2f:I[703058,["/_next/static/immutable/chunks/3bhq_5eh1d760.js","/_next/static/immutable/chunks/1855-ogyi8eh4.js","/_next/static/immutable/chunks/2pfsjpn6k6zlg.js","/_next/static/immutable/chunks/26c7v3_3uwnwu.js","/_next/static/immutable/chunks/25a3ozcrvi1ff.js","/_next/static/immutable/chunks/2r4wx50nvjh_4.js","/_next/static/immutable/chunks/23fsw06hsi5b1.js","/_next/static/immutable/chunks/06_yt270h41rg.js","/_next/static/immutable/chunks/3ezsiz-7shkna.js","/_next/static/immutable/chunks/20x2y96ldu5wx.js","/_next/static/immutable/chunks/2lxntcm3pd1_h.js","/_next/static/immutable/chunks/00dgco8irq3jw.js","/_next/static/immutable/chunks/00nwe-kq0rboc.js","/_next/static/immutable/chunks/2051ffx3xzio9.js"],"PaperListPageClient"] 30:T758,Janus kinase 2 (JAK2) gene fusions characterize cytotoxic cutaneous T-cell lymphoma (CTCL) including primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma (pcAETCL). The identification of these fusions is rarely reported in indolent CTCL. To characterize patients with CTCL to better understand the diagnostic, prognostic, and therapeutic significance of this molecular alteration in CTCL. A retrospective case series of patients with CTCL with JAK2 fusions identified between the years 2000 and 2025. Fusions were identified by a custom RNA sequencing panel and by a targeted hybrid-capture-based next-generation DNA sequencing-based panel. The study included a single referral cancer center in the US. Overall, 43 patients (12 female [27.9%] and 31 male individuals [72.1%]; median [range] age, 45 [16-65] years) with CTCL who were found to have JAK2 gene fusions during evaluation and follow-up were included. Thirty-eight of the 43 identified patients (88.4%) with fusions of JAK2 and 10 different gene partners (most frequently ATXN2L, CAPRIN1, and PCM1) had mycosis fungoides (MF), CD30-positive lymphoproliferative disorders (LPD), or overlap presentations, whereas 4 pcAETCL and 1 peripheral T-cell lymphoma not otherwise specified were identified. Secondary genetic events included mutations of epigenetic and transcriptional regulators. Neither mutational burden, type, or fusion partner distinguished cases with early-stage or aggressive CTCL. This case series found that JAK2 fusions were seen in aggressive cytotoxic CTCL as well as in T-cell lymphomas with more indolent behavior, possibly representing a precursor lesion to aggressive evolution with age and comorbidities. The prominence of these fusions supports a potentially larger role for JAK2 targeting in patients with early-stage MF, CD30-positive LPD, or overlap presentations.31:Te18, Importance Janus kinase 2 ( JAK2 ) gene fusions characterize cytotoxic cutaneous T-cell lymphoma (CTCL) including primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma (pcAETCL). The identification of these fusions is rarely reported in indolent CTCL. Objective To characterize patients with CTCL to better understand the diagnostic, prognostic, and therapeutic significance of this molecular alteration in CTCL. Design, Setting, and Participants A retrospective case series of patients with CTCL with JAK2 fusions identified between the years 2000 and 2025. Fusions were identified by a custom RNA sequencing panel and by a targeted hybrid-capture-based next-generation DNA sequencing-based panel. The study included a single referral cancer center in the US. Results Overall, 43 patients (12 female [27.9%] and 31 male individuals [72.1%]; median [range] age, 45 [16-65] years) with CTCL who were found to have JAK2 gene fusions during evaluation and follow-up were included. Thirty-eight of the 43 identified patients (88.4%) with fusions of JAK2 and 10 different gene partners (most frequently ATXN2L , CAPRIN1, and PCM1 ) had mycosis fungoides (MF), CD30-positive lymphoproliferative disorders (LPD), or overlap presentations, whereas 4 pcAETCL and 1 peripheral T-cell lymphoma not otherwise specified were identified. Secondary genetic events included mutations of epigenetic and transcriptional regulators. Neither mutational burden, type, or fusion partner distinguished cases with early-stage or aggressive CTCL. Conclusions and Relevance This case series found that JAK2 fusions were seen in aggressive cytotoxic CTCL as well as in T-cell lymphomas with more indolent behavior, possibly representing a precursor lesion to aggressive evolution with age and comorbidities. The prominence of these fusions supports a potentially larger role for JAK2 targeting in patients with early-stage MF, CD30-positive LPD, or overlap presentations. 32:T4ab,This manuscript provides expert recommendations on the role of allogeneic haematopoietic cell transplantation (allo-HCT) for cutaneous T-cell lymphoma (CTCL), specifically mycosis fungoides (MF) and Sezary syndrome (SS). Critical aspects such as patient selection, timing, and bridging therapy are addressed, as well as donor source, conditioning regimens and post-transplant management. These consensus guidelines are based on a thorough literature review and discussions among leading dermatologists and haematologists. These recommendations aim to harmonize clinical practice towards improving patient outcomes in these rare but aggressive lymphomas. It is of critical importance to consider allo-HCT early in the management of eligible patients with high-risk disease. Advanced stage, large-cell transformation, relapsed or refractory disease following systemic treatment, and N3-stage lymph node involvement are indicators that should trigger consultation with a transplant haematologist in parallel with a donor search. Early interaction between dermatologists and transplant haematologists is vital to avoiding delays, which can significantly impact post-transplant outcomes and survival.33:T4ed,AbstractThis manuscript provides expert recommendations on the role of allogeneic haematopoietic cell transplantation (allo‐HCT) for cutaneous T‐cell lymphoma (CTCL), specifically mycosis fungoides (MF) and Sezary syndrome (SS). Critical aspects such as patient selection, timing, and bridging therapy are addressed, as well as donor source, conditioning regimens and post‐transplant management. These consensus guidelines are based on a thorough literature review and discussions among leading dermatologists and haematologists. These recommendations aim to harmonize clinical practice towards improving patient outcomes in these rare but aggressive lymphomas. It is of critical importance to consider allo‐HCT early in the management of eligible patients with high‐risk disease. Advanced stage, large‐cell transformation, relapsed or refractory disease following systemic treatment, and N3‐stage lymph node involvement are indicators that should trigger consultation with a transplant haematologist in parallel with a donor search. Early interaction between dermatologists and transplant haematologists is vital to avoiding delays, which can significantly impact post‐transplant outcomes and survival.34:T4bd,While brentuximab vedotin (BV) and radiotherapy (RTx) are established treatment options for CD30-positive cutaneous T-cell lymphoma (CTCL), data on their simultaneous or sequential use regarding efficacy and tolerability remain scarce. In this retrospective analysis, we evaluated the combination of BV and RTx in patients with CD30-positive CTCL. We included 14 CD30-positive CTCL patients from six German cancer centers receiving BV; RTx was initiated within a timeframe of 3 months prior/after BV treatment. RTx was mainly applied as a low-dose scheme. Adverse events of any grade occurred in 71% of patients, most commonly peripheral neuropathy, neutropenia, and radiodermatitis. Thirteen patients achieved a complete or partial remission as best overall response, however, 50% of all patients showed disease progression. At a median follow-up of 14.4 months, median progression-free survival was 12.0 months, with a 1-year rate of 34.0%. The simultaneous or sequential use of RTx during BV treatment was feasible and well tolerated. Future randomized investigations are needed to identify the benefits of this combination treatment regimen as well as adequate dosing of BV and RTx in a prospective manner.35:T625,SummaryBackground and ObjectivesWhile brentuximab vedotin (BV) and radiotherapy (RTx) are established treatment options for CD30‐positive cutaneous T‐cell lymphoma (CTCL), data on their simultaneous or sequential use regarding efficacy and tolerability remain scarce. In this retrospective analysis, we evaluated the combination of BV and RTx in patients with CD30‐positive CTCL.Patients and MethodsWe included 14 CD30‐positive CTCL patients from six German cancer centers receiving BV; RTx was initiated within a timeframe of 3 months prior/after BV treatment. RTx was mainly applied as a low‐dose scheme.ResultsAdverse events of any grade occurred in 71% of patients, most commonly peripheral neuropathy, neutropenia, and radiodermatitis. Thirteen patients achieved a complete or partial remission as best overall response, however, 50% of all patients showed disease progression. At a median follow‐up of 14.4 months, median progression‐free survival was 12.0 months, with a 1‐year rate of 34.0%.ConclusionsThe simultaneous or sequential use of RTx during BV treatment was feasible and well tolerated. Future randomized investigations are needed to identify the benefits of this combination treatment regimen as well as adequate dosing of BV and RTx in a prospective manner.36:T560,Staphylococcus aureus is suspected to fuel disease activity in cutaneous T-cell lymphomas. In this study, we investigate the effect of a recombinant, antibacterial protein, endolysin (XZ.700), on S. aureus skin colonization and malignant T-cell activation. We show that endolysin strongly inhibits the proliferation of S. aureus isolated from cutaneous T-cell lymphoma skin and significantly decreases S. aureus bacterial cell counts in a dose-dependent manner. Likewise, ex vivo colonization of both healthy and lesional skin by S. aureus is profoundly inhibited by endolysin. Moreover, endolysin inhibits the patient-derived S. aureus induction of IFNγ and the IFNγ-inducible chemokine CXCL10 in healthy skin. Whereas patient-derived S. aureus stimulates activation and proliferation of malignant T cells in vitro through an indirect mechanism involving nonmalignant T cells, endolysin strongly inhibits the effects of S. aureus on activation (reduced CD25 and signal transducer and activator of transcription 5 phosphorylation) and proliferation (reduced Ki-67) of malignant T cells and cell lines in the presence of nonmalignant T cells. Taken together, we provide evidence that endolysin XZ.700 inhibits skin colonization, chemokine expression, and proliferation of pathogenic S. aureus and blocks their potential tumor-promoting effects on malignant T cells.25:[[["$","script","0",{"type":"application/ld+json","dangerouslySetInnerHTML":{"__html":"{\"@context\":\"https://schema.org\",\"@type\":\"CollectionPage\",\"name\":\"Cutaneous T-Cell Lymphoma: condition Research & Clinical Takeaways\",\"description\":\"Explore peer-reviewed papers on Cutaneous T-Cell Lymphoma (condition). Clinician-written summaries and actionable practice insights. Updated daily.\",\"url\":\"https://www.reachrx.ai/hub/tag/condition/Cutaneous%20T-Cell%20Lymphoma\",\"breadcrumb\":{\"@type\":\"BreadcrumbList\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https://www.reachrx.ai\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Research Hub\",\"item\":\"https://www.reachrx.ai/hub\"},{\"@type\":\"ListItem\",\"position\":3,\"name\":\"Conditions\",\"item\":\"https://www.reachrx.ai/hub/tag/condition\"},{\"@type\":\"ListItem\",\"position\":4,\"name\":\"Cutaneous T-Cell Lymphoma\",\"item\":\"https://www.reachrx.ai/hub/tag/condition/Cutaneous%20T-Cell%20Lymphoma\"}]}}"}}]],["$","$L2f",null,{"title":"Cutaneous T-Cell Lymphoma: Research & Clinical Takeaways","description":"Discover peer-reviewed research on Cutaneous T-Cell Lymphoma with concise clinician summaries and next-step guidance.","papers":[{"doi":"10.1097/dad.0000000000003431","pmid":"42715545","title":"Recurrent Primary Cutaneous Anaplastic Large Cell Lymphoma With T-Cell Receptor-ϒδ Phenotype and DUSP22-IRF4 Unbalanced Rearrangement: A Rare and Diagnostically Challenging Presentation","journal_title":"The American Journal of Dermatopathology","journal_issn":"0193-1091","published_at":"2026-09-09T00:00:00.000Z","url":"https://doi.org/10.1097/dad.0000000000003431","source_score":3,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-09-14T06:23:21.581Z","updated_at":"2026-09-14T06:23:21.581Z","tags":[{"paper_doi":"10.1097/dad.0000000000003431","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1097/dad.0000000000003431","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1097/dad.0000000000003431","tag_type":"condition","value":"Cutaneous T-Cell Lymphoma","value_numeric":null},{"paper_doi":"10.1097/dad.0000000000003431","tag_type":"condition","value":"Primary Cutaneous Anaplastic Large Cell Lymphoma","value_numeric":null},{"paper_doi":"10.1097/dad.0000000000003431","tag_type":"generic","value":"fluorescence in situ hybridization","value_numeric":null},{"paper_doi":"10.1097/dad.0000000000003431","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1097/dad.0000000000003431","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1097/dad.0000000000003431","tag_type":"modality","value":"Radiation Therapy","value_numeric":null},{"paper_doi":"10.1097/dad.0000000000003431","tag_type":"sample_size","value":"n=1","value_numeric":1},{"paper_doi":"10.1097/dad.0000000000003431","tag_type":"sex","value":"male","value_numeric":null},{"paper_doi":"10.1097/dad.0000000000003431","tag_type":"study_design","value":"Case Report","value_numeric":null},{"paper_doi":"10.1097/dad.0000000000003431","tag_type":"warning","value":"Study design tag 'Case Report' is unambiguous, but the level of evidence (5) reflects the inherent limitations of single-patient case reports.","value_numeric":null},{"paper_doi":"10.1097/dad.0000000000003431","tag_type":"warning","value":"The clinical outcome following the recurrent diagnosis is not described, limiting assessment of prognosis in this rare variant.","value_numeric":null},{"paper_doi":"10.1097/dad.0000000000003431","tag_type":"warning","value":"This is a single case report; findings and diagnostic criteria should not be broadly generalized without further evidence.","value_numeric":null}],"summaries":{"what_studied":"A case report of a 78-year-old man with recurrent primary cutaneous anaplastic large cell lymphoma (pcALCL) featuring the rare co-occurrence of a TCR-γδ phenotype and DUSP22-IRF4 unbalanced rearrangement, presenting 5 years after complete remission with radiation therapy.","key_result":"Histopathology, immunohistochemistry (CD30+, TCR-δ+, LEF1+, TIA-1−, predominantly p-STAT3−, ALK−), and FISH confirmed pcALCL with TCR-γδ phenotype and an unbalanced DUSP22-IRF4 rearrangement — an exceedingly rare combination not previously well characterized.","limitations":"Single case report limits generalizability; the clinical outcome after the recurrence diagnosis is not reported; the distinction between balanced vs. unbalanced DUSP22-IRF4 rearrangement relied on indirect IHC markers rather than direct sequencing confirmation.","practice_takeaway":"When evaluating CD30+ cutaneous lymphomas, consider FISH for DUSP22-IRF4 rearrangement and TCR subtype immunostaining (TCR-δ, TCR-β) even in presumed pcALCL, as co-occurrence of TCR-γδ phenotype and DUSP22-IRF4 alteration poses significant diagnostic challenges. LEF1 positivity and TIA-1 negativity may help distinguish unbalanced from balanced DUSP22-IRF4 rearrangements."}},{"doi":"10.1016/j.jid.2026.07.022","pmid":"42678334","title":"Beyond the ceiling: A critical analysis of microRNA research in cutaneous T-cell lymphoma and a roadmap forward","journal_title":"Journal of Investigative Dermatology","journal_issn":"0022-202X","published_at":"2026-09-01T00:00:00.000Z","url":"https://doi.org/10.1016/j.jid.2026.07.022","source_score":1,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-09-07T06:30:45.621Z","updated_at":"2026-09-07T06:30:45.621Z","tags":[{"paper_doi":"10.1016/j.jid.2026.07.022","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.07.022","tag_type":"brand","value":"Cobomarsen","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.07.022","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.07.022","tag_type":"condition","value":"Cutaneous T-Cell Lymphoma","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.07.022","tag_type":"generic","value":"cobomarsen","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.07.022","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.07.022","tag_type":"level_of_evidence","value":"5","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.07.022","tag_type":"modality","value":"Anti-MicroRNA","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.07.022","tag_type":"modality","value":"MicroRNA Therapy","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.07.022","tag_type":"study_design","value":"Narrative Review","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.07.022","tag_type":"warning","value":"Cobomarsen's current regulatory/trial status (as of publication) is not specified in the abstract.","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.07.022","tag_type":"warning","value":"No sample size is reported; this is a review article with no primary patient cohort.","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.07.022","tag_type":"warning","value":"Sex distribution of underlying studied populations is not reported in the abstract.","value_numeric":null},{"paper_doi":"10.1016/j.jid.2026.07.022","tag_type":"warning","value":"Study design is described as a 'critical analysis' and roadmap — it is a narrative review, not a systematic review or meta-analysis; level of evidence assigned accordingly.","value_numeric":null}],"summaries":{"what_studied":"This review critically analyzes 15+ years of microRNA (miRNA) research in cutaneous T-cell lymphoma (CTCL), covering oncogenic/tumor-suppressive networks, JAK/STAT-miRNA signaling, diagnostic classifiers, and therapeutic miRNA targeting (including Cobomarsen, an anti-miR-155 agent).","key_result":"Despite extensive study, no miRNA diagnostic has reached clinical practice; the authors attribute translational stagnation to two core limitations: reliance on bulk-tissue profiling and intrinsic miRNA biology (modest, pleiotropic pathway regulation).","limitations":"This is a narrative/critical review without systematic search methods or meta-analysis, so conclusions reflect expert synthesis rather than pooled quantitative evidence. No primary patient data or effect sizes are reported.","practice_takeaway":"miRNA-based diagnostics and therapeutics for CTCL remain investigational; clinicians should not expect validated miRNA assays in the near term. Future advances hinge on single-cell profiling, multiomics integration, and multicenter validation studies."}},{"doi":"10.1111/ddg.70555","pmid":"42615429","title":"Infectious risk during mogamulizumab therapy in mycosis fungoides and Sézary syndrome","journal_title":"JDDG: Journal der Deutschen Dermatologischen Gesellschaft","journal_issn":"1610-0379","published_at":"2026-08-19T00:00:00.000Z","url":"https://doi.org/10.1111/ddg.70555","source_score":3,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-28T06:25:27.223Z","updated_at":"2026-08-28T06:25:27.223Z","tags":[{"paper_doi":"10.1111/ddg.70555","tag_type":"brand","value":"Poteligeo","value_numeric":null},{"paper_doi":"10.1111/ddg.70555","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1111/ddg.70555","tag_type":"condition","value":"Cutaneous T-Cell Lymphoma","value_numeric":null},{"paper_doi":"10.1111/ddg.70555","tag_type":"condition","value":"Mycosis Fungoides","value_numeric":null},{"paper_doi":"10.1111/ddg.70555","tag_type":"condition","value":"Sézary Syndrome","value_numeric":null},{"paper_doi":"10.1111/ddg.70555","tag_type":"generic","value":"mogamulizumab","value_numeric":null},{"paper_doi":"10.1111/ddg.70555","tag_type":"impact_flag","value":"safety_signal","value_numeric":null},{"paper_doi":"10.1111/ddg.70555","tag_type":"modality","value":"Anti-CCR4 Monoclonal Antibody","value_numeric":null},{"paper_doi":"10.1111/ddg.70555","tag_type":"warning","value":"The full text of this paper was not provided — only metadata (title, DOI, journal, publication date). All structured outputs are inferred from the title alone. Numerical results, study design, sample size, age group, sex distribution, and level of evidence could not be extracted or verified. Treat all tags and summaries as provisional pending full-text review.","value_numeric":null}],"summaries":{"what_studied":"This study evaluated the infectious risk associated with mogamulizumab therapy in patients with mycosis fungoides (MF) and Sézary syndrome (SS), a population already prone to immunosuppression-related infections.","limitations":"The full text was not available for review; key numerical outcomes, sample size, study design specifics, and comparator details could not be verified from the provided source data.","practice_takeaway":"Clinicians treating MF/SS with mogamulizumab should maintain heightened vigilance for infectious complications given the drug's immunomodulatory mechanism; prophylactic strategies may warrant consideration."}},{"doi":"10.2340/actadv.v106.adv-2026-0693","pmid":"42516099","title":"Fungal Skin Infections in Cutaneous T-cell Lymphoma Patients under Mogamulizumab Treatment","journal_title":"Acta Dermato-Venereologica","journal_issn":"1651-2057","published_at":"2026-07-28T00:00:00.000Z","url":"https://doi.org/10.2340/actadv.v106.adv-2026-0693","source_score":1,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-31T13:37:20.118Z","updated_at":"2026-07-31T13:37:20.118Z","tags":[{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"brand","value":"Poteligeo","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"condition","value":"Cutaneous T-Cell Lymphoma","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"condition","value":"Fungal Skin Infection","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"condition","value":"Mycosis Fungoides","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"condition","value":"Sézary Syndrome","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"generic","value":"amphotericin B","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"generic","value":"ciclopirox","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"generic","value":"fluconazole","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"generic","value":"mogamulizumab","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"generic","value":"terbinafine","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"impact_flag","value":"safety_signal","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"level_of_evidence","value":"4","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"modality","value":"Anti-CCR4 Monoclonal Antibody","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"sample_size","value":"n=5","value_numeric":5},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"study_design","value":"Case Series","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"warning","value":"Causality between mogamulizumab and fungal infections cannot be established from this case series given the heavily pre-treated, immunocompromised patient population.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"warning","value":"The brand name 'Poteligeo' is inferred from mogamulizumab's known proprietary name; it is not explicitly stated in the paper.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0693","tag_type":"warning","value":"The incidence of 41.7% is from a very small single-center cohort (5/12 patients) and should be interpreted with extreme caution.","value_numeric":null}],"summaries":{"what_studied":"A single-center case series of 5 CTCL patients (1 MF, 4 SS) who developed fungal skin infections during mogamulizumab therapy between January 2021 and December 2024 at a German university center, representing 41.7% (5/12) of all mogamulizumab-treated patients at that institution.","key_result":"5 of 12 mogamulizumab-treated CTCL patients (41.7%) developed fungal skin infections at a mean of 10.6 months after therapy initiation; pathogens included *Candida* spp. (40%), *T. tonsurans* (20%), *T. rubrum* (20%), and *T. interdigitale* (20%). All infections were mild (CTCAE grade 1: 40%; grade 2: 60%); 60% required systemic antifungal therapy (terbinafine or fluconazole) after topical monotherapy failed.","limitations":"- Very small case series (n=5) from a single center; no control group or incidence comparison to other CTCL therapies.\n- Fungal infections may be attributable to the heavily pre-treated, immunocompromised baseline rather than mogamulizumab specifically.\n- Retrospective design with potential for ascertainment bias; infections could be underdiagnosed in the broader mogamulizumab literature.","practice_takeaway":"Clinicians should actively screen CTCL patients on mogamulizumab for fungal skin infections, as these can mimic CTCL lesions or mogamulizumab-associated rash (MAR) and may go undetected. Currently no antifungal prophylaxis guidelines exist for this population; a low threshold for mycological workup (culture, skin scraping, biopsy) is warranted."}},{"doi":"10.2340/actadv.v106.adv-2026-0463","pmid":"42454691","title":"Psychological Distress, Symptom Burden and Quality of Life in Patients with Mycosis Fungoides and Sézary Syndrome","journal_title":"Acta Dermato-Venereologica","journal_issn":"1651-2057","published_at":"2026-07-15T00:00:00.000Z","url":"https://doi.org/10.2340/actadv.v106.adv-2026-0463","source_score":1,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-07-18T13:39:58.580Z","updated_at":"2026-07-18T13:39:58.580Z","tags":[{"paper_doi":"10.2340/actadv.v106.adv-2026-0463","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0463","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0463","tag_type":"condition","value":"Cutaneous T-Cell Lymphoma","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0463","tag_type":"condition","value":"Mycosis Fungoides","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0463","tag_type":"condition","value":"Psoriasis","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0463","tag_type":"condition","value":"Sézary Syndrome","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0463","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0463","tag_type":"level_of_evidence","value":"4","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0463","tag_type":"sample_size","value":"n=60","value_numeric":60},{"paper_doi":"10.2340/actadv.v106.adv-2026-0463","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0463","tag_type":"study_design","value":"Cross-Sectional Observational Study","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0463","tag_type":"warning","value":"Stage-related differences (early vs. advanced MF/SS) did not reach statistical significance, likely due to the small advanced-disease subgroup (n=12); trends should be interpreted with caution.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0463","tag_type":"warning","value":"The psoriasis comparator cohort (GÖTHA) was collected separately and may differ in data collection period and context, which could introduce unmeasured confounding.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0463","tag_type":"warning","value":"Treatment data were not collected for the MF/SS cohort, so the influence of active therapies on symptom burden and psychological outcomes cannot be assessed.","value_numeric":null},{"paper_doi":"10.2340/actadv.v106.adv-2026-0463","tag_type":"warning","value":"VAS fatigue comparison between MF/SS and psoriasis did not reach significance (p=0.49) despite a numerically higher median in MF/SS, which may reflect insufficient power.","value_numeric":null}],"summaries":{"what_studied":"This cross-sectional questionnaire study assessed psychological distress (MADRS-S, HADS), symptom burden (VAS for pruritus, pain, fatigue), and quality of life (DLQI) in 60 patients with mycosis fungoides (MF) or Sézary syndrome (SS) in Western Sweden (80% early-stage), and compared outcomes with 139 psoriasis patients.","key_result":"Most MF/SS patients reported minimal depression, anxiety, and QoL impairment; however, moderate-to-severe depression occurred in 36% of advanced vs. 16% of early-stage patients, and moderate-to-severe QoL impairment (DLQI ≥6) in 33% vs. 17%, respectively. Fatigue was the dominant symptom (median VAS 3) and correlated strongly with depression (MADRS-S ρ=0.60, HADS-D ρ=0.63), anxiety (ρ=0.49), and impaired QoL (ρ=0.53; all p<0.001). Pruritus strongly predicted QoL impairment (ρ=0.67, p<0.001). Compared to psoriasis, MF/SS patients had lower DLQI (median 1 vs. 3, p=0.001) and lower pain scores (median VAS 0 vs. 0.8, p<0.001), but similar fatigue.","limitations":"- Small sample with only 12 advanced-stage patients severely limits statistical power to detect stage-related differences.\n- Cross-sectional design at a single time point across varied disease phases and treatments; treatment data were not collected.\n- Disease severity was not quantified with validated tools (e.g., mSWAT), preventing correlation of skin burden with patient-reported outcomes.","practice_takeaway":"Routinely screen MF/SS patients — especially those with advanced disease — for fatigue and depression, as both are under-recognized drivers of QoL impairment beyond what skin severity scores capture. Pruritus control should remain a priority given its strong independent association with reduced QoL."}},{"doi":"10.1001/jamadermatol.2026.1793","pmid":"42307910","title":"Clinicopathologic Features and Long-Term Outcomes of Adult Hypopigmented Mycosis Fungoides","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2026-06-17T00:00:00.000Z","url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13276674/","source_score":19,"is_retracted":false,"is_open_access":true,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-08-20T06:47:49.446Z","updated_at":"2026-08-20T06:47:49.446Z","tags":[{"paper_doi":"10.1001/jamadermatol.2026.1793","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1793","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1793","tag_type":"condition","value":"Cutaneous T-Cell Lymphoma","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1793","tag_type":"condition","value":"Hypopigmented Mycosis Fungoides","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1793","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1793","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1793","tag_type":"modality","value":"Skin-Directed Therapy","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1793","tag_type":"sample_size","value":"n=224","value_numeric":224},{"paper_doi":"10.1001/jamadermatol.2026.1793","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1793","tag_type":"study_design","value":"Retrospective Multicenter Cohort Study","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1793","tag_type":"warning","value":"Full text was inaccessible (publisher access check); summary is based solely on the abstract and results section provided.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1793","tag_type":"warning","value":"Racial/ethnic composition (83% Black) reflects referral center demographics and may limit generalizability to other populations.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2026.1793","tag_type":"warning","value":"The paper's DOI and publication date (2026) are consistent with today's date, but the abstract notes data analysis ran through December 2025 — findings are current but the study is newly published and independent replication is lacking.","value_numeric":null}],"summaries":{"what_studied":"This retrospective multicenter cohort study (6 US tertiary centers, Jan 2011–Oct 2023) examined clinicopathologic features and long-term outcomes in 224 adults (≥18 years) with biopsy-confirmed hypopigmented mycosis fungoides (HMF), with a median follow-up of 39 months.","key_result":"98% presented with early-stage disease; 77% achieved complete or partial response to treatment (26% CR, 51% PR), mostly with skin-directed therapy alone (90%). Only 6% progressed to a higher stage overall, and just 2% of early-stage patients advanced to advanced-stage disease. Peripheral blood TCR monoclonality (found in 27%) was linked to poorer treatment response but not to disease progression.","limitations":"Retrospective design with inherent selection bias from tertiary referral centers; immunophenotyping and peripheral blood TCR data were unavailable for a substantial subset of patients (only 141/224 had immunophenotyping, only 85/224 had TCR testing); median follow-up of ~39 months may be insufficient to capture late progression events.","practice_takeaway":"Adult HMF, which disproportionately affects Black women, follows an indolent course and responds well to skin-directed therapy regardless of CD8 vs. CD4 predominance or mixed-variant presentation. Peripheral blood TCR monoclonality may signal lower treatment response and warrants closer monitoring, but should not alone escalate therapy."}},{"doi":"10.1097/pas.0000000000002572","pmid":"42210690","title":"TRBC1 Immunohistochemistry Utilization in Formalin-fixed Paraffin-embedded Tissue as an Adjunct to T-cell Clonality Testing in the Assessment of Cutaneous Lymphoproliferative Disorders","journal_title":"American Journal of Surgical Pathology","journal_issn":"0147-5185","published_at":"2026-05-29T00:00:00.000Z","url":"https://doi.org/10.1097/pas.0000000000002572","source_score":2,"is_retracted":false,"is_open_access":false,"raw_metadata":{"pubmed":true,"crossref":true,"unpaywall":true},"created_at":"2026-06-05T13:26:47.139Z","updated_at":"2026-06-05T13:26:47.139Z","tags":[{"paper_doi":"10.1097/pas.0000000000002572","tag_type":"age_group","value":"mixed","value_numeric":null},{"paper_doi":"10.1097/pas.0000000000002572","tag_type":"category","value":"Surgery","value_numeric":null},{"paper_doi":"10.1097/pas.0000000000002572","tag_type":"condition","value":"Cutaneous Lymphoproliferative Disorder","value_numeric":null},{"paper_doi":"10.1097/pas.0000000000002572","tag_type":"condition","value":"Cutaneous T-Cell Lymphoma","value_numeric":null},{"paper_doi":"10.1097/pas.0000000000002572","tag_type":"condition","value":"Mycosis Fungoides","value_numeric":null},{"paper_doi":"10.1097/pas.0000000000002572","tag_type":"generic","value":"TRBC1","value_numeric":null},{"paper_doi":"10.1097/pas.0000000000002572","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1097/pas.0000000000002572","tag_type":"level_of_evidence","value":"4","value_numeric":null},{"paper_doi":"10.1097/pas.0000000000002572","tag_type":"modality","value":"Immunohistochemistry","value_numeric":null},{"paper_doi":"10.1097/pas.0000000000002572","tag_type":"sample_size","value":"n=67","value_numeric":67},{"paper_doi":"10.1097/pas.0000000000002572","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1097/pas.0000000000002572","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1097/pas.0000000000002572","tag_type":"warning","value":"Sample size of 67 total (36 cases + 31 controls) is small; subgroup analyses (MF vs. non-MF, intraepithelial vs. full infiltrate) are based on even smaller subsets, increasing uncertainty around reported sensitivities.","value_numeric":null},{"paper_doi":"10.1097/pas.0000000000002572","tag_type":"warning","value":"The full text body was not accessible in the provided content (only publisher permission guidelines were returned); all extracted data are derived exclusively from the abstract.","value_numeric":null},{"paper_doi":"10.1097/pas.0000000000002572","tag_type":"warning","value":"TRBC1 is referenced as a nonproprietary target/marker rather than a conventional drug; it has been tagged under 'generic' for discoverability but is a diagnostic antibody, not a therapeutic agent.","value_numeric":null}],"summaries":{"what_studied":"This study evaluated TRBC1 immunohistochemistry (IHC) in FFPE skin biopsies as an adjunct marker for T-cell clonality across 36 cases of cutaneous T-cell lymphoproliferative disorders (including mycosis fungoides and non-MF CTCL) and 31 polyclonal controls, comparing results to molecular clonality testing.","key_result":"Overall concordance of TRBC1 IHC with molecular clonality testing was 79% (sensitivity 64%, specificity 97%, PPV 96%, NPV 70%); sensitivity improved to 72% in MF cases but dropped to 50% when restricted to intraepithelial T-cells only, and to 56% in non-MF CTCL. Optimal discrimination used thresholds of ≤20% or ≥80% (or ≤30%/≥70%) TRBC1-positive cells among CD3+ T-cells.","limitations":"- Modest sample size (36 cases, 31 controls) limits generalizability.\n- TRBC1 IHC cannot detect clonality in TCR-γ/δ T-cell disorders (no β-chain expression), limiting applicability to a subset of CTCLs.\n- Sensitivity for intraepithelial lymphocytes is notably low (50%), restricting utility in assessment strategies focused on that compartment.","practice_takeaway":"TRBC1 IHC on FFPE skin biopsies is a useful adjunct for clonality assessment in mycosis fungoides—especially when evaluating the full dermal infiltrate rather than intraepithelial cells alone—but should not replace molecular clonality testing given its limited sensitivity. It offers no signal in TCR-γ/δ lymphomas, so confirm T-cell receptor subtype before applying this marker."}},{"doi":"10.1001/jamadermatol.2025.4688","pmid":"41296329","title":"JAK2 Fusions in Adult Patients With Mycosis Fungoides and CD30 Lymphoproliferative Disorders","journal_title":"JAMA Dermatology","journal_issn":"2168-6068","published_at":"2025-11-26T00:00:00.000Z","url":"https://doi.org/10.1001/jamadermatol.2025.4688","source_score":7,"is_retracted":false,"is_open_access":false,"raw_metadata":{"ooir":{"day":"2025-11-27","doi":"10.1001/jamadermatol.2025.4688","days":"7","issn":"2168-6068","rank":"8","field":"Clinical Medicine","score":"7","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1001/jamadermatol.2025.4688","title":"JAK2 Fusions in Adult Patients With Mycosis Fungoides and CD30 Lymphoproliferative Disorders.","journal":"JAMA dermatology","methods":"","results":"Overall, 43 patients (12 female [27.9%] and 31 male individuals [72.1%]; median [range] age, 45 [16-65] years) with CTCL who were found to have JAK2 gene fusions during evaluation and follow-up were included. Thirty-eight of the 43 identified patients (88.4%) with fusions of JAK2 and 10 different gene partners (most frequently ATXN2L, CAPRIN1, and PCM1) had mycosis fungoides (MF), CD30-positive lymphoproliferative disorders (LPD), or overlap presentations, whereas 4 pcAETCL and 1 peripheral T-cell lymphoma not otherwise specified were identified. Secondary genetic events included mutations of epigenetic and transcriptional regulators. Neither mutational burden, type, or fusion partner distinguished cases with early-stage or aggressive CTCL.","abstract":"$30","keywords":[],"pubmed_id":"41296329","conclusions":"","publication_date":"2025-11-26T00:00:00"},"crossref":{"DOI":"10.1001/jamadermatol.2025.4688","URL":"https://doi.org/10.1001/jamadermatol.2025.4688","ISSN":["2168-6068"],"link":[{"URL":"https://jamanetwork.com/journals/jamadermatology/articlepdf/2841751/jamadermatology_geller_2025_oi_250057_1763325626.56939.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["JAK2 Fusions in Adult Patients With Mycosis Fungoides and CD30 Lymphoproliferative Disorders"],"author":[{"given":"Shamir","family":"Geller","sequence":"first","affiliation":[{"name":"Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"Department of Dermatology, Weill Cornell Medicine, New York, New York"}]},{"given":"Viviane","family":"Liao","sequence":"additional","affiliation":[{"name":"Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}]},{"given":"Leore","family":"Lavin","sequence":"additional","affiliation":[{"name":"Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York"}]},{"given":"Haiming","family":"Tang","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}]},{"given":"Mia","family":"Do","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}]},{"given":"Andrea","family":"Moy","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}]},{"given":"Cesar A.","family":"Virgen","sequence":"additional","affiliation":[{"name":"Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}]},{"given":"Liam","family":"Donnelly","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"}]},{"given":"Melissa P.","family":"Pulitzer","sequence":"additional","affiliation":[{"name":"Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, New York, New York"},{"name":"Department of Pathology and Laboratory Medicine, Weill Cornell Medicine, New York, New York"}]}],"issued":{"date-parts":[[2025,11,26]]},"member":"10","prefix":"10.1001","source":"Crossref","volume":null,"created":{"date-time":"2025-11-26T16:31:37Z","timestamp":1764174697000,"date-parts":[[2025,11,26]]},"indexed":{"date-time":"2025-11-26T16:36:34Z","timestamp":1764174994921,"date-parts":[[2025,11,26]]},"subject":[],"abstract":"$31","language":"en","relation":{},"resource":{"primary":{"URL":"https://jamanetwork.com/journals/jamadermatology/fullarticle/2841751"}},"subtitle":[],"deposited":{"date-time":"2025-11-26T16:31:38Z","timestamp":1764174698000,"date-parts":[[2025,11,26]]},"issn-type":[{"type":"print","value":"2168-6068"}],"published":{"date-parts":[[2025,11,26]]},"publisher":"American Medical Association (AMA)","reference":[{"DOI":"10.1182/blood.2022016690","key":"doi250057r1","year":"2023","issue":"2","author":"Gluud","volume":"141","first-page":"180","unstructured":null,"article-title":"Malignant T cells induce skin barrier defects through cytokine-mediated JAK/STAT signaling in cutaneous T-cell lymphoma.","journal-title":"Blood","doi-asserted-by":"publisher"},{"DOI":"10.3324/haematol.2020.274506","key":"doi250057r2","year":"2022","issue":"3","author":"Bastidas Torres","volume":"107","first-page":"702","unstructured":null,"article-title":"Deregulation of JAK2 signaling underlies primary cutaneous CD8+ aggressive epidermotropic cytotoxic T-cell lymphoma.","journal-title":"Haematologica","doi-asserted-by":"publisher"},{"DOI":"10.1182/blood.2021012536","key":"doi250057r3","year":"2021","issue":"23","author":"Lee","volume":"138","first-page":"2435","unstructured":null,"article-title":"Primary cytotoxic T-cell lymphomas harbor recurrent targetable alterations in the JAK-STAT pathway.","journal-title":"Blood","doi-asserted-by":"publisher"},{"DOI":"10.1007/s00428-022-03372-x","key":"doi250057r4","year":"2022","issue":"6","author":"Rodriguez-Sevilla","volume":"481","first-page":"967","unstructured":null,"article-title":"PCM1:JAK2 fusion associates with an atypical form of mycosis fungoides.","journal-title":"Virchows Arch","doi-asserted-by":"publisher"},{"DOI":"10.18632/oncotarget.21790","key":"doi250057r5","year":"2017","issue":"61","author":"Panagopoulos","volume":"8","first-page":"103775","unstructured":null,"article-title":"Fusion of the genes ataxin 2 like, ATXN2L, and Janus kinase 2, JAK2, in cutaneous CD4 positive T-cell lymphoma.","journal-title":"Oncotarget","doi-asserted-by":"publisher"},{"DOI":"10.1182/blood-2018-01-830968","key":"doi250057r6","year":"2018","issue":"20","author":"Sharma","volume":"131","first-page":"2262","unstructured":null,"article-title":"Recurrent STAT3-JAK2 fusions in indolent T-cell lymphoproliferative disorder of the gastrointestinal tract.","journal-title":"Blood","doi-asserted-by":"publisher"},{"DOI":"10.1016/j.xjidi.2021.100034","key":"doi250057r7","year":"2021","issue":"3","author":"Wobser","volume":"1","first-page":null,"unstructured":null,"article-title":"Oncogenic mutations and gene fusions in CD30-positive lymphoproliferations and clonally related mycosis fungoides occurring in the same patients.","journal-title":"JID Innov","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jid.2020.02.019","key":"doi250057r8","year":"2020","issue":"10","author":"Maurus","volume":"140","first-page":"2023","unstructured":null,"article-title":"Recurrent oncogenic JAK and STAT alterations in cutaneous CD30-positive lymphoproliferative disorders.","journal-title":"J Invest Dermatol","doi-asserted-by":"publisher"},{"DOI":"10.1097/PAS.0000000000001708","key":"doi250057r9","year":"2021","issue":"7","author":"Fitzpatrick","volume":"45","first-page":"895","unstructured":null,"article-title":"JAK2 rearrangements are a recurrent alteration in CD30+ systemic t-cell lymphomas with anaplastic morphology.","journal-title":"Am J Surg Pathol","doi-asserted-by":"publisher"},{"DOI":"10.1111/tbj.14205","key":"doi250057r10","year":"2021","issue":"4","author":"Quesada","volume":"27","first-page":"314","unstructured":null,"article-title":"Next generation sequencing of breast implant-associated anaplastic large cell lymphomas reveals a novel STAT3-JAK2 fusion among other activating genetic alterations within the JAK-STAT pathway.","journal-title":"Breast J","doi-asserted-by":"publisher"},{"DOI":"10.1128/MCB.20.10.3387-3395.2000","key":"doi250057r11","year":"2000","issue":"10","author":"Saharinen","volume":"20","first-page":"3387","unstructured":null,"article-title":"Regulation of the Jak2 tyrosine kinase by its pseudokinase domain.","journal-title":"Mol Cell Biol","doi-asserted-by":"publisher"},{"DOI":"10.1038/nsmb.2099","key":"doi250057r12","year":"2011","issue":"9","author":"Ungureanu","volume":"18","first-page":"971","unstructured":null,"article-title":"The pseudokinase domain of JAK2 is a dual-specificity protein kinase that negatively regulates cytokine signaling.","journal-title":"Nat Struct Mol Biol","doi-asserted-by":"publisher"}],"short-title":[],"content-domain":{"domain":[],"crossmark-restriction":false},"original-title":[],"container-title":["JAMA Dermatology"],"reference-count":12,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,11,26]]},"references-count":12,"short-container-title":["JAMA Dermatol"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1001/jamadermatol.2025.4688","is_oa":false,"title":"JAK2 Fusions in Adult Patients With Mycosis Fungoides and CD30 Lymphoproliferative Disorders","updated":"2025-11-27T02:22:14+00:00","published_date":"2025-11-26","best_oa_location":null}},"created_at":"2025-11-30T07:03:02.464Z","updated_at":"2025-12-02T07:03:10.886Z","tags":[{"paper_doi":"10.1001/jamadermatol.2025.4688","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.4688","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.4688","tag_type":"condition","value":"CD30-Positive Lymphoproliferative Disorder","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.4688","tag_type":"condition","value":"Cutaneous T-Cell Lymphoma","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.4688","tag_type":"condition","value":"Mycosis Fungoides","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.4688","tag_type":"condition","value":"Primary Cutaneous Aggressive Epidermotropic Cytotoxic T-Cell Lymphoma","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.4688","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.4688","tag_type":"level_of_evidence","value":"6","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.4688","tag_type":"sample_size","value":"n=43","value_numeric":43},{"paper_doi":"10.1001/jamadermatol.2025.4688","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.4688","tag_type":"study_design","value":"Case Series","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.4688","tag_type":"warning","value":"The abstract does not report treatment response or survival outcomes.","value_numeric":null},{"paper_doi":"10.1001/jamadermatol.2025.4688","tag_type":"warning","value":"Title specifies adults, but the reported age range includes a 16-year-old.","value_numeric":null}],"summaries":{"what_studied":"A retrospective case series from a single US referral cancer center (2000–2025) describing cutaneous T-cell lymphoma (CTCL) patients with JAK2 fusions detected by custom RNA sequencing and targeted DNA panels. The study characterized diagnostic, prognostic, and therapeutic context of these fusions.","key_result":"Among 43 patients (12 female, 31 male; median age 45 [16–65]), 38/43 (88.4%) with JAK2 fusions had mycosis fungoides, CD30‑positive lymphoproliferative disorders, or overlap; 4 had pcAETCL and 1 had PTCL‑NOS. Ten fusion partners were identified (most often ATXN2L, CAPRIN1, PCM1); secondary events involved epigenetic/transcriptional regulators, and fusion partner, type, or mutational burden did not distinguish early‑stage from aggressive CTCL.","limitations":"Retrospective, single‑center case series. Detection relied on custom sequencing panels, which may limit generalizability.","practice_takeaway":"JAK2 fusions are present across the CTCL spectrum, including MF and CD30‑positive LPD, not just in aggressive cytotoxic variants. In this cohort, fusion partner, type, and burden did not stratify early vs aggressive disease, so the fusion profile alone should not guide risk assessment."}},{"doi":"10.1111/jdv.70042","pmid":"41031482","title":"Allogeneic haematopoietic cell transplant in cutaneous T‐cell lymphomas: Recommendations from the EBMT PH&G Committee","journal_title":"Journal of the European Academy of Dermatology and Venereology","journal_issn":"0926-9959","published_at":"2025-10-01T00:00:00.000Z","url":"https://doi.org/10.1111/jdv.70042","source_score":1,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2025-10-05","doi":"10.1111/jdv.70042","days":"7","issn":"0926-9959","rank":"10","field":"Clinical Medicine","score":"1","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1111/jdv.70042","title":"Allogeneic haematopoietic cell transplant in cutaneous T-cell lymphomas: Recommendations from the EBMT PH&G Committee.","journal":"Journal of the European Academy of Dermatology and Venereology : JEADV","methods":"","results":"","abstract":"$32","keywords":["Sézary syndrome","allogeneic transplantation","cutaneous T‐cell","lymphomas","mycosis fungoides","skin cancer"],"pubmed_id":"41031482","conclusions":"","publication_date":"2025-10-01T00:00:00"},"crossref":{"DOI":"10.1111/jdv.70042","URL":"https://doi.org/10.1111/jdv.70042","ISSN":["0926-9959","1468-3083"],"link":[{"URL":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/jdv.70042","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Allogeneic haematopoietic cell transplant in cutaneous T‐cell lymphomas: Recommendations from the EBMT PH&G Committee"],"author":[{"given":"Gandhi","family":"Damaj","sequence":"first","affiliation":[{"name":"Caen University Hospital Hematology Institute, Normandy University, School of Medicine Caen France"}]},{"given":"Adèle","family":"de Masson","sequence":"additional","affiliation":[{"name":"Department of Dermatology Saint‐Louis Hospital, AP‐HP, National Reference Center for Cutaneous Lymphomas, Institut du Cancer AP‐HP Nord, Université Paris Cité Paris France"}]},{"given":"Peter","family":"Dreger","sequence":"additional","affiliation":[{"name":"Department of Medicine V University of Heidelberg Heidelberg Germany"}]},{"given":"Ali","family":"Bazarbachi","sequence":"additional","affiliation":[{"name":"Chair of the EBMT Lymphoma Working Party, Bone Marrow Transplantation Program, Department of Internal Medicine American University of Beirut Beirut Lebanon"}]},{"given":"Philipp","family":"Berning","sequence":"additional","affiliation":[{"name":"Department of Medicine A University Hospital Münster Münster Germany"}]},{"given":"Rafael F.","family":"Duarte","sequence":"additional","affiliation":[{"name":"Hospital Universitario Puerta de Hierro Majadahonda Madrid Spain"}]},{"given":"Christopher P.","family":"Fox","sequence":"additional","affiliation":[{"name":"School of Medicine, University of Nottingham Nottingham UK"}]},{"given":"Emmanuella","family":"Guenova","sequence":"additional","affiliation":[{"name":"University Institute and Clinic for Immuno‐Dermatology, Medical Faculty Johannes Kepler University, Secretary of the EORTC Cutaneous Lymphoma Tumor Group Linz Austria"}]},{"given":"Olivier","family":"Hermine","sequence":"additional","affiliation":[{"name":"Service d'Hématologie Adultes, Institut Necker Enfants Malades, Unité INSERM U1153, Hôpital Universitaire Necker‐Enfants Malades, AP‐HP, Université Paris Cité and Imagine Institute Paris France"}]},{"given":"Charalampia","family":"Kyriakou","sequence":"additional","affiliation":[{"name":"Secretary of the EBMT LWP, Department of Hematology University College London Hospital London UK"}]},{"given":"Alina","family":"Tanase","sequence":"additional","affiliation":[{"name":"Fundeni Clinical Institute University of Medicine and Pharmacy Carol Davila Bucharest Romania"}]},{"given":"Olivier","family":"Tournilhac","sequence":"additional","affiliation":[{"name":"Department of Hematology and Cell Therapy Clermont‐Ferrand University Hospital, UCA, EA7453 Chelter CIC‐1405 Clermont‐Ferrand France"}]},{"given":"Wojiech","family":"Jurczak","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology Maria Sklodowska Curie National Research Institute of Oncology Krakow Poland"}]},{"given":"Imke E.","family":"Karsten","sequence":"additional","affiliation":[{"name":"Department of Medicine A University Hospital Münster Münster Germany"}]},{"given":"Stéphanie Nguyen","family":"Quoc","sequence":"additional","affiliation":[{"name":"Department of Hematology and Cellular Therapies Sorbonne University Pitié‐Salpêtrière Hospital Paris France"}]},{"given":"Yasmina","family":"Serroukh","sequence":"additional","affiliation":[{"name":"Department of Hematology Erasmus MC Cancer Institute, University Medical Center Rotterdam Rotterdam The Netherlands"}]},{"given":"Federico","family":"Stella","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Istituto Nazionale Dei Tumori Milano, University of Milano Milan Italy"}]},{"given":"Gerald","family":"Wulf","sequence":"additional","affiliation":[{"name":"Department of Hematology and Medical Oncology University Hospital Goettingen Goettingen Germany"}]},{"given":"Anna","family":"Sureda","sequence":"additional","affiliation":[{"name":"Clinical Hematology Department, Institut Català d'Oncologia – L'hospitalet, Institut de Recerca Biomèdica de Bellvitge (IDIBELL) Universitat de Barcelona Barcelona Spain"}]},{"given":"Evangelia","family":"Papadavid","sequence":"additional","affiliation":[{"name":"Department of Dermatology National and Kapodistrian University of Athens, Attikon University Hospital Athens Greece"}]},{"given":"Pablo L.","family":"Ortiz‐Romero","sequence":"additional","affiliation":[{"name":"Department of Dermatology Institute i+12, Hospital 12 de Octubre Medical School University Complutense Madrid Spain"}]},{"given":"Annalisa","family":"Ruggeri","sequence":"additional","affiliation":[{"name":"Co‐Chair of the Practice Harmonisation and Guidelines Committee of EBMT and Chair of the CTIWP of the EBMT. Hematology and BMT Unit IRCCS San Raffaele Hospital Milan Italy"}]},{"given":"Isabel","family":"Sánchez‐Ortega","sequence":"additional","affiliation":[{"name":"Secretary of the Practice Harmonisation and Guidelines Committee of EBMT; EBMT Medical Officer, Executive Office Barcelona Spain"}]},{"given":"Julia J.","family":"Scarisbrick","sequence":"additional","affiliation":[{"name":"University Hospital Birmingham and University of Birmingham Birmingham UK"}]},{"given":"Ibrahim","family":"Yakoub‐Agha","sequence":"additional","affiliation":[{"name":"Chair of the EBMT Practice Harmonisation and Guidelines Committee; Lille University Hospital, Lille University, INSERM U1286, Infinite Lille France"}]},{"given":"Francesco","family":"Onida","sequence":"additional","affiliation":[{"name":"Co‐Chair of the Practice Harmonisation and Guidelines Committee of the EBMT; Hematology and BMT Centre, ASST Fatebenefratelli‐Sacco University of Milan Milan Italy"}]},{"given":"Norbert","family":"Schmitz","sequence":"additional","affiliation":[{"name":"Department of Medicine A University Hospital Münster Münster Germany"}]}],"issued":{"date-parts":[[2025,10]]},"member":"311","prefix":"10.1111","source":"Crossref","volume":null,"archive":["Portico"],"created":{"date-time":"2025-10-01T10:01:09Z","timestamp":1759312869000,"date-parts":[[2025,10,1]]},"indexed":{"date-time":"2025-10-02T00:41:49Z","timestamp":1759365709081,"date-parts":[[2025,10,2]]},"license":[{"URL":"http://creativecommons.org/licenses/by-nc/4.0/","start":{"date-time":"2025-10-01T00:00:00Z","timestamp":1759276800000,"date-parts":[[2025,10,1]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":"$33","language":"en","relation":{},"resource":{"primary":{"URL":"https://onlinelibrary.wiley.com/doi/10.1111/jdv.70042"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","order":0,"value":"2025-04-10"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","order":2,"value":"2025-07-11"},{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":3,"value":"2025-10-01"}],"deposited":{"date-time":"2025-10-01T10:01:10Z","timestamp":1759312870000,"date-parts":[[2025,10,1]]},"issn-type":[{"type":"print","value":"0926-9959"},{"type":"electronic","value":"1468-3083"}],"published":{"date-parts":[[2025,10]]},"publisher":"Wiley","reference":[{"DOI":"10.1111/bjd.19644","key":"e_1_2_15_2_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.3390/cancers12102921","key":"e_1_2_15_3_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1182/blood-2018-11-881268","key":"e_1_2_15_4_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.17258","key":"e_1_2_15_5_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2014.10.006","key":"e_1_2_15_6_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2011.39.8065","key":"e_1_2_15_7_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1093/annonc/mdt480","key":"e_1_2_15_8_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/cncr.21449","key":"e_1_2_15_9_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s00277-014-2121-1","key":"e_1_2_15_10_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(18)30379-6","key":"e_1_2_15_11_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(17)31266-7","key":"e_1_2_15_12_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2015.61.7142","key":"e_1_2_15_13_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.18541","key":"e_1_2_15_14_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S0140-6736(23)00329-X","key":"e_1_2_15_15_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/s41409-020-01197-3","key":"e_1_2_15_16_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2010.29.3241","key":"e_1_2_15_17_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.bbmt.2019.08.019","key":"e_1_2_15_18_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1080/14737140.2024.2305356","key":"e_1_2_15_19_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ejca.2023.113343","key":"e_1_2_15_20_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jtct.2024.08.020","key":"e_1_2_15_21_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/s41409-023-01958-w","key":"e_1_2_15_22_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1182/blood.2021012057","key":"e_1_2_15_23_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2014.10.014","key":"e_1_2_15_24_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2010.28.9066","key":"e_1_2_15_25_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2014.57.5597","key":"e_1_2_15_26_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.eclinm.2024.102679","key":"e_1_2_15_27_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1007/s12185-024-03753-9","key":"e_1_2_15_28_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2016.67.8250","key":"e_1_2_15_29_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1182/blood-2007-03-055749","key":"e_1_2_15_30_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2009.27.7665","key":"e_1_2_15_31_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1097/PAT.0000000000000166","key":"e_1_2_15_32_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jaad.2013.09.007","key":"e_1_2_15_33_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.clml.2017.11.004","key":"e_1_2_15_34_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1080/10428194.2020.1790555","key":"e_1_2_15_35_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.2340/00015555-2950","key":"e_1_2_15_36_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1182/bloodadvances.2020001627","key":"e_1_2_15_37_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/s41409-024-02236-z","key":"e_1_2_15_38_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1126/scitranslmed.3007420","key":"e_1_2_15_39_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.18806","key":"e_1_2_15_40_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.18215","key":"e_1_2_15_41_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/bjd.19220","key":"e_1_2_15_42_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2009.25.8301","key":"e_1_2_15_43_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.ijrobp.2024.11.011","key":"e_1_2_15_44_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1080/10428194.2019.1658106","key":"e_1_2_15_45_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/s41409-023-02122-0","key":"e_1_2_15_46_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":null,"key":"e_1_2_15_47_1","year":"2024","issue":null,"author":"Onida F","volume":"59","first-page":null,"unstructured":null,"article-title":"Allogeneic hematopoietic cell transplantation in patients with advanced mycosis fungoides and Sézary syndrome: a retrospective analysis including 63 consecutive patients with long‐term median follow‐up","journal-title":"Bone Marrow Transplant","doi-asserted-by":null},{"DOI":"10.1182/bloodadvances.2021005899","key":"e_1_2_15_48_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.jtct.2022.11.028","key":"e_1_2_15_49_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.bbmt.2018.06.026","key":"e_1_2_15_50_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.2006.08.0952","key":"e_1_2_15_51_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1200/JCO.19.02408","key":"e_1_2_15_52_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.2991/chi.k.210529.001","key":"e_1_2_15_53_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1002/ajh.27531","key":"e_1_2_15_54_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1177/09636897241270401","key":"e_1_2_15_55_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1080/10428194.2024.2376164","key":"e_1_2_15_56_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1038/s41409-018-0400-5","key":"e_1_2_15_57_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S2352-3026(19)30256-X","key":"e_1_2_15_58_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1111/jdv.15661","key":"e_1_2_15_59_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/j.clml.2020.06.020","key":"e_1_2_15_60_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"},{"DOI":"10.1016/S1470-2045(24)00508-4","key":"e_1_2_15_61_1","year":null,"issue":null,"author":null,"volume":null,"first-page":null,"unstructured":null,"article-title":null,"journal-title":null,"doi-asserted-by":"publisher"}],"short-title":[],"update-policy":"https://doi.org/10.1002/crossmark_policy","alternative-id":["10.1111/jdv.70042"],"article-number":"jdv.70042","content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Journal of the European Academy of Dermatology and Venereology"],"reference-count":60,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,10]]},"references-count":60,"short-container-title":["Acad Dermatol Venereol"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1111/jdv.70042","is_oa":true,"title":"Allogeneic haematopoietic cell transplant in cutaneous T‐cell lymphomas: Recommendations from the EBMT PH&G Committee","updated":"2025-10-06T00:09:52+00:00","published_date":"2025-10-01","best_oa_location":{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jdv.70042","pmh_id":null,"url_for_pdf":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/jdv.70042","url_for_landing_page":"https://doi.org/10.1111/jdv.70042"}}},"created_at":"2025-10-10T09:56:52.931Z","updated_at":"2025-10-10T09:56:52.931Z","tags":[{"paper_doi":"10.1111/jdv.70042","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1111/jdv.70042","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1111/jdv.70042","tag_type":"condition","value":"Cutaneous T-Cell Lymphoma","value_numeric":null},{"paper_doi":"10.1111/jdv.70042","tag_type":"condition","value":"Mycosis Fungoides","value_numeric":null},{"paper_doi":"10.1111/jdv.70042","tag_type":"condition","value":"Sezary Syndrome","value_numeric":null},{"paper_doi":"10.1111/jdv.70042","tag_type":"impact_flag","value":"confirms_prior","value_numeric":null},{"paper_doi":"10.1111/jdv.70042","tag_type":"level_of_evidence","value":"7","value_numeric":null},{"paper_doi":"10.1111/jdv.70042","tag_type":"modality","value":"Allogeneic Hematopoietic Cell Transplantation","value_numeric":null},{"paper_doi":"10.1111/jdv.70042","tag_type":"study_design","value":"Guideline","value_numeric":null},{"paper_doi":"10.1111/jdv.70042","tag_type":"warning","value":"Recommendations against routine MRD monitoring or maintenance reflect insufficient evidence, not proof of no benefit.","value_numeric":null},{"paper_doi":"10.1111/jdv.70042","tag_type":"warning","value":"Some donor-source comparisons (especially haploidentical) derive from small cohorts and may not generalize.","value_numeric":null},{"paper_doi":"10.1111/jdv.70042","tag_type":"warning","value":"This is a consensus guideline synthesizing heterogeneous studies rather than a single trial.","value_numeric":null}],"summaries":{"what_studied":"Expert consensus guidance from the EBMT PH&G Committee on when and how to use allogeneic haematopoietic cell transplantation for cutaneous T‑cell lymphomas (mycosis fungoides and Sézary syndrome), covering referral criteria, timing/bridging, donor selection, conditioning/GVHD prophylaxis, and post‑transplant care.","key_result":"In the CUTALLO propensity‑matched prospective study (n=99), allo‑HCT prolonged PFS to 9.0 months vs 3.0 months with conventional therapy (HR 0.38, 95% CI 0.21–0.69; p<0.0001). Historical/pooled benchmarks for allo‑HCT show 5‑year OS 38% and PFS 26% (EBMT registry), and OS 51% at 1 year and 40% at 3 years with PFS 42% at 1 year and 33% at 3 years (meta‑analysis).","limitations":"Recommendations rest largely on retrospective series, registry analyses, and small prospective cohorts, with heterogeneous conditioning, donor sources, and peri‑transplant practices. Evidence for haploidentical donors, modern GVHD prophylaxis (e.g., PTCy), MRD monitoring, and maintenance strategies remains limited or inconclusive.","practice_takeaway":"Refer high‑risk MF/SS early; aim for CR or deep response (VGPR or mSWAT <10) before RIC allo‑HCT, prefer MRD/MUD donors, and observe a 6‑week washout after pre‑HCT mogamulizumab. Manage relapse with immunosuppression taper and DLI, adding site‑directed therapy or TSEB as indicated; routine post‑HCT MRD monitoring or maintenance is not recommended."}},{"doi":"10.1111/ddg.15897","pmid":"41025752","title":"Brentuximab vedotin and radiotherapy for CD30‐positive cutaneous T‐cell lymphoma – a retrospective multicenter analysis","journal_title":"JDDG: Journal der Deutschen Dermatologischen Gesellschaft","journal_issn":"1610-0379","published_at":"2025-09-30T00:00:00.000Z","url":"https://doi.org/10.1111/ddg.15897","source_score":7,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2025-10-01","doi":"10.1111/ddg.15897","days":"14","issn":"1610-0379","rank":"10","field":"Clinical Medicine","score":"7","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1111/ddg.15897","title":"Brentuximab vedotin and radiotherapy for CD30-positive cutaneous T-cell lymphoma - a retrospective multicenter analysis.","journal":"Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG","methods":"","results":"Adverse events of any grade occurred in 71% of patients, most commonly peripheral neuropathy, neutropenia, and radiodermatitis. Thirteen patients achieved a complete or partial remission as best overall response, however, 50% of all patients showed disease progression. At a median follow-up of 14.4 months, median progression-free survival was 12.0 months, with a 1-year rate of 34.0%.","abstract":"$34","keywords":["Brentuximab vedotin","cutaneous T‐cell lymphoma","radiotherapy"],"pubmed_id":"41025752","conclusions":"","publication_date":"2025-09-30T00:00:00"},"crossref":{"DOI":"10.1111/ddg.15897","URL":"https://doi.org/10.1111/ddg.15897","ISSN":["1610-0379","1610-0387"],"link":[{"URL":"https://onlinelibrary.wiley.com/doi/pdf/10.1111/ddg.15897","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"page":null,"type":"journal-article","issue":null,"score":1,"title":["Brentuximab vedotin and radiotherapy for CD30‐positive cutaneous T‐cell lymphoma – a retrospective multicenter analysis"],"author":[{"given":"Patrick","family":"Schummer","sequence":"first","affiliation":[{"name":"Department of Dermatology Venereology and Allergology University Hospital Würzburg Würzburg Germany"}]},{"given":"Caroline","family":"Glatzel","sequence":"additional","affiliation":[{"name":"Department of Dermatology Venereology and Allergology University Hospital Würzburg Würzburg Germany"}]},{"given":"Philipp","family":"Schrüfer","sequence":"additional","affiliation":[{"name":"Department of Dermatology Venereology and Allergology University Hospital Würzburg Würzburg Germany"},{"name":"Skinmed AG Lenzburg Switzerland"}]},{"given":"Ingulf","family":"Lawrenz","sequence":"additional","affiliation":[{"name":"Department of Radiotherapy and Radiooncology University Hospital Würzburg Würzburg Germany"}]},{"given":"Gabor","family":"Dobos","sequence":"additional","affiliation":[{"name":"Department of Dermatology Venereology and Allergology Charité – Universitätsmedizin Berlin Berlin Germany"}]},{"given":"Ulrike","family":"Wehkamp","sequence":"additional","affiliation":[{"name":"Department of Dermatology and Allergy University Hospital Schleswig‐Holstein Kiel Germany"},{"name":"Medical School Hamburg Hamburg Germany"}]},{"given":"Svea","family":"Hüning","sequence":"additional","affiliation":[{"name":"Department of Dermatology Hospital of Dortmund Dortmund Germany"},{"name":"Hautarztpraxis Schwelm Schwelm Germany"}]},{"given":"René","family":"Stranzenbach","sequence":"additional","affiliation":[{"name":"Dermatologie‐Gevelsberg Gevelsberg Germany"}]},{"given":"Jan P.","family":"Nicolay","sequence":"additional","affiliation":[{"name":"Department of Dermatology University Medical Center Mannheim Mannheim Germany"}]},{"given":"Matthias","family":"Goebeler","sequence":"additional","affiliation":[{"name":"Department of Dermatology Venereology and Allergology University Hospital Würzburg Würzburg Germany"}]},{"given":"Marion","family":"Wobser","sequence":"additional","affiliation":[{"name":"Department of Dermatology Venereology and Allergology University Hospital Würzburg Würzburg Germany"}]}],"issued":{"date-parts":[[2025,9,30]]},"member":"311","prefix":"10.1111","source":"Crossref","volume":null,"archive":["Portico"],"created":{"date-time":"2025-09-30T12:50:01Z","timestamp":1759236601000,"date-parts":[[2025,9,30]]},"indexed":{"date-time":"2025-10-01T15:57:00Z","timestamp":1759334220461,"date-parts":[[2025,10,1]]},"license":[{"URL":"http://creativecommons.org/licenses/by/4.0/","start":{"date-time":"2025-09-30T00:00:00Z","timestamp":1759190400000,"date-parts":[[2025,9,30]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":"$35","language":"en","relation":{},"resource":{"primary":{"URL":"https://onlinelibrary.wiley.com/doi/10.1111/ddg.15897"}},"subtitle":[],"assertion":[{"name":"received","group":{"name":"publication_history","label":"Publication History"},"label":"Received","order":0,"value":"2025-02-28"},{"name":"accepted","group":{"name":"publication_history","label":"Publication History"},"label":"Accepted","order":2,"value":"2025-06-16"},{"name":"published","group":{"name":"publication_history","label":"Publication History"},"label":"Published","order":3,"value":"2025-09-30"}],"deposited":{"date-time":"2025-09-30T12:50:05Z","timestamp":1759236605000,"date-parts":[[2025,9,30]]},"issn-type":[{"type":"print","value":"1610-0379"},{"type":"electronic","value":"1610-0387"}],"published":{"date-parts":[[2025,9,30]]},"publisher":"Wiley","reference":[{"DOI":"10.1002/hon.2850","key":"e_1_2_8_2_1","year":"2021","issue":"1","author":"Kempf W","volume":"39","first-page":"46","unstructured":null,"article-title":"Cutaneous T‐cell lymphomas‐An update 2021","journal-title":"Hematol Oncol","doi-asserted-by":"crossref"},{"DOI":"10.1093/annonc/mdy133","key":"e_1_2_8_3_1","year":"2018","issue":"4","author":"Willemze R","volume":"29","first-page":"iv30","unstructured":null,"article-title":"Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow‐up","journal-title":"Ann Oncol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0140-6736(17)31266-7","key":"e_1_2_8_4_1","year":"2017","issue":"10094","author":"Prince HM","volume":"390","first-page":"555","unstructured":null,"article-title":"Brentuximab vedotin or physician's choice in CD30‐positive cutaneous T‐cell lymphoma (ALCANZA): an international, open‐label, randomised, phase 3, multicentre trial","journal-title":"Lancet","doi-asserted-by":"crossref"},{"DOI":"10.1182/bloodadvances.2021004710","key":"e_1_2_8_5_1","year":"2021","issue":"23","author":"Horwitz SM","volume":"5","first-page":"5098","unstructured":null,"article-title":"Randomized phase 3 ALCANZA study of brentuximab vedotin vs physician's choice in cutaneous T‐cell lymphoma: final data","journal-title":"Blood Adv","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.ijrobp.2015.01.008","key":"e_1_2_8_6_1","year":"2015","issue":"1","author":"Specht L","volume":"92","first-page":"32","unstructured":null,"article-title":"Modern radiation therapy for primary cutaneous lymphomas: field and dose guidelines from the International Lymphoma Radiation Oncology Group","journal-title":"Int J Radiat Oncol Biol Phys","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.det.2015.05.006","key":"e_1_2_8_7_1","year":"2015","issue":"4","author":"Tandberg DJ","volume":"33","first-page":"703","unstructured":null,"article-title":"Radiation Therapy for Cutaneous T‐Cell Lymphomas","journal-title":"Dermatol Clin","doi-asserted-by":"crossref"},{"DOI":"10.1002/ajh.26299","key":"e_1_2_8_8_1","year":"2021","issue":"10","author":"Hristov AC","volume":"96","first-page":"1313","unstructured":null,"article-title":"Cutaneous T‐cell lymphomas: 2021 update on diagnosis, risk‐stratification, and management","journal-title":"Am J Hematol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.ejca.2024.115064","key":"e_1_2_8_9_1","year":"2024","issue":null,"author":"Elsayad K","volume":"212","first-page":null,"unstructured":null,"article-title":"Radiotherapy in cutaneous lymphomas: Recommendations from the EORTC cutaneous lymphoma tumour group","journal-title":"Eur J Cancer","doi-asserted-by":"crossref"},{"DOI":"10.1111/dth.13478","key":"e_1_2_8_10_1","year":"2020","issue":"4","author":"Georgakopoulos I","volume":"33","first-page":null,"unstructured":null,"article-title":"Low dose total skin electron beam therapy for the management of T cell cutaneous lymphomas","journal-title":"Dermatol Ther","doi-asserted-by":"crossref"},{"DOI":null,"key":"e_1_2_8_11_1","year":"2020","issue":"15","author":"Song S","volume":"38","first-page":null,"unstructured":null,"article-title":"Phase Ib study of brentuximab vedotin (BV) with low‐dose total skin electron beam (LD‐TSEB) for treatment of mycosis fungoides (MF) and Sezary syndrome (SS)","journal-title":"J Clin Oncol","doi-asserted-by":null},{"DOI":"10.1002/ajh.23925","key":"e_1_2_8_12_1","year":"2015","issue":"4","author":"Dozzo M","volume":"90","first-page":"E73","unstructured":null,"article-title":"Brentuximab vedotin in combination with extended field radiotherapy as salvage treatment for primary refractory Hodgkin lymphoma","journal-title":"Am J Hematol","doi-asserted-by":"crossref"},{"DOI":"10.1182/blood-2016-03-703470","key":"e_1_2_8_13_1","year":"2016","issue":"11","author":"Kumar A","volume":"128","first-page":"1458","unstructured":null,"article-title":"Brentuximab vedotin and AVD followed by involved‐site radiotherapy in early stage, unfavorable risk Hodgkin lymphoma","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":"10.1159/000479224","key":"e_1_2_8_14_1","year":"2017","issue":"3","author":"Montana W","volume":"10","first-page":"795","unstructured":null,"article-title":"Near Complete Response in a Patient with Classical Hodgkin Lymphoma Treated with Brentuximab Vedotin Concurrent with Radiation Therapy","journal-title":"Case Rep Oncol","doi-asserted-by":"crossref"},{"DOI":"10.14740/jh534","key":"e_1_2_8_15_1","year":"2019","issue":"3","author":"Floyd EG","volume":"8","first-page":"132","unstructured":null,"article-title":"Combined Modality Treatment With Brentuximab Vedotin and Radiation Therapy for Primary Cutaneous Anaplastic Large Cell Lymphoma: A Case Report","journal-title":"J Hematol","doi-asserted-by":"crossref"},{"DOI":"10.1182/blood-2007-03-055749","key":"e_1_2_8_16_1","year":"2007","issue":"6","author":"Olsen E","volume":"110","first-page":"1713","unstructured":null,"article-title":"Revisions to the staging and classification of mycosis fungoides and Sezary syndrome: a proposal of the International Society for Cutaneous Lymphomas (ISCL) and the cutaneous lymphoma task force of the European Organization of Research and Treatment of Cancer (EORTC)","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":"10.1093/bjd/ljac012","key":"e_1_2_8_17_1","year":"2023","issue":"1","author":"Oymanns M","volume":"188","first-page":"145","unstructured":null,"article-title":"Near complete responses to concurrent brentuximab vedotin and ultra‐hypofractionated low‐dose total skin electron beam radiation in advanced cutaneous T‐cell lymphoma","journal-title":"The British journal of dermatology","doi-asserted-by":"crossref"},{"DOI":"10.1158/0008-5472.CAN-14-1931","key":"e_1_2_8_18_1","year":"2015","issue":"7","author":"Buckel L","volume":"75","first-page":"1376","unstructured":null,"article-title":"Tumor radiosensitization by monomethyl auristatin E: mechanism of action and targeted delivery","journal-title":"Cancer Res","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.adro.2023.101279","key":"e_1_2_8_19_1","year":"2023","issue":"6","author":"Wu SY","volume":"8","first-page":null,"unstructured":null,"article-title":"Safety of Concurrent Radiation Therapy With Brentuximab Vedotin in the Treatment of Lymphoma","journal-title":"Adv Radiat Oncol","doi-asserted-by":"crossref"},{"DOI":"10.1111/jdv.18563","key":"e_1_2_8_20_1","year":"2023","issue":"1","author":"Muniesa C","volume":"37","first-page":"57","unstructured":null,"article-title":"Brentuximab vedotin in the treatment of cutaneous T‐cell lymphomas: Data from the Spanish Primary Cutaneous Lymphoma Registry","journal-title":"J Eur Acad Dermatol Venereol","doi-asserted-by":"crossref"},{"DOI":"10.1111/ddg.14342","key":"e_1_2_8_21_1","year":"2021","issue":"3","author":"Stranzenbach R","volume":"19","first-page":"383","unstructured":null,"article-title":"Combination of brentuximab‐vedotin with skin‐directed therapies extends the time to the next therapeutic line in patients with cutaneous T‐cell lymphoma","journal-title":"J Dtsch Dermatol Ges","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.ijrobp.2024.11.011","key":"e_1_2_8_22_1","year":"2025","issue":"4","author":"Elsayad K","volume":"121","first-page":"1006","unstructured":null,"article-title":"Real‐World Pattern‐of‐Care Analysis of Primary Cutaneous Lymphomas Radiation Therapy Among European Organisation for Research and Treatment of Cancer Members","journal-title":"Int J Radiat Oncol Biol Phys","doi-asserted-by":"crossref"}],"short-title":[],"update-policy":"https://doi.org/10.1002/crossmark_policy","alternative-id":["10.1111/ddg.15897"],"article-number":"ddg.15897","content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"original-title":[],"container-title":["JDDG: Journal der Deutschen Dermatologischen Gesellschaft"],"reference-count":21,"published-online":{"date-time":null,"timestamp":null,"date-parts":[[2025,9,30]]},"references-count":21,"short-container-title":["J Deutsche Derma Gesell"],"is-referenced-by-count":0},"unpaywall":{"doi":"10.1111/ddg.15897","is_oa":true,"title":"Brentuximab vedotin and radiotherapy for CD30‐positive cutaneous T‐cell lymphoma – a retrospective multicenter analysis","updated":"2025-10-03T07:17:10+00:00","published_date":"2025-09-30","best_oa_location":{"url":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ddg.15897","pmh_id":null,"url_for_pdf":"https://onlinelibrary.wiley.com/doi/pdfdirect/10.1111/ddg.15897","url_for_landing_page":"https://doi.org/10.1111/ddg.15897"}}},"created_at":"2025-10-11T07:13:56.506Z","updated_at":"2025-10-15T07:01:11.375Z","tags":[{"paper_doi":"10.1111/ddg.15897","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1111/ddg.15897","tag_type":"age_group","value":"older_adult","value_numeric":null},{"paper_doi":"10.1111/ddg.15897","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1111/ddg.15897","tag_type":"condition","value":"Cutaneous T-Cell Lymphoma","value_numeric":null},{"paper_doi":"10.1111/ddg.15897","tag_type":"generic","value":"brentuximab vedotin","value_numeric":null},{"paper_doi":"10.1111/ddg.15897","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1111/ddg.15897","tag_type":"level_of_evidence","value":"3","value_numeric":null},{"paper_doi":"10.1111/ddg.15897","tag_type":"modality","value":"Antibody-Drug Conjugate","value_numeric":null},{"paper_doi":"10.1111/ddg.15897","tag_type":"modality","value":"Radiotherapy","value_numeric":null},{"paper_doi":"10.1111/ddg.15897","tag_type":"sample_size","value":"n=14","value_numeric":14},{"paper_doi":"10.1111/ddg.15897","tag_type":"sex","value":"mixed","value_numeric":null},{"paper_doi":"10.1111/ddg.15897","tag_type":"study_design","value":"Retrospective Cohort Study","value_numeric":null},{"paper_doi":"10.1111/ddg.15897","tag_type":"warning","value":"Global response was assessed at BV discontinuation or last follow-up, not at a uniform timepoint; the 1-year PFS confidence interval is very wide due to small N.","value_numeric":null},{"paper_doi":"10.1111/ddg.15897","tag_type":"warning","value":"One patient had a non-MF CTCL subtype with missing staging, adding clinical heterogeneity.","value_numeric":null},{"paper_doi":"10.1111/ddg.15897","tag_type":"warning","value":"Single-arm retrospective series from six centers with heterogeneous radiation doses/schedules and BV modifications; efficacy versus BV alone is uncertain.","value_numeric":null}],"summaries":{"what_studied":"A retrospective multicenter series evaluated 14 patients with CD30‑positive cutaneous T‑cell lymphoma treated with brentuximab vedotin (BV) plus radiotherapy started within 3 months before/after BV or given simultaneously; low‑dose RTx was common (≤12 Gy in 57%). Median follow‑up was 14.4 months.","key_result":"Adverse events occurred in 71% (10/14), with grade ≥3 in 21% (3/14); common events were peripheral neuropathy, neutropenia, and radiodermatitis. Best overall response was CR 14% (2/14) and PR 79% (11/14); at last assessment CR 14%, PR 29%, SD 7%, PD 50%; median PFS was 12.0 months (95% CI 7.3–NA) with 1‑year PFS 34.0% (95% CI 12.9–90.1).","limitations":"Very small sample (n=14) with heterogeneous RTx modalities, doses, and BV adjustments; retrospective, single‑arm design without a control group; predominantly advanced‑stage disease and unsystematic documentation limit generalizability.","practice_takeaway":"Combining BV with RTx (sequentially or concurrently) was feasible and generally well tolerated, with expected toxicities and no new safety signals. Use caution with higher RTx doses and close sequencing, as severe hematologic events were observed with 30 Gy schedules and near‑term BV."}},{"doi":"10.1016/j.jid.2023.01.039","pmid":"36889662","title":"Endolysin Inhibits Skin Colonization by Patient-Derived Staphylococcus Aureus and Malignant T-Cell Activation in Cutaneous T-Cell Lymphoma","journal_title":"Journal of Investigative Dermatology","journal_issn":"0022-202X","published_at":"2023-03-09T00:00:00.000Z","url":"https://doi.org/10.1016/j.jid.2023.01.039","source_score":679,"is_retracted":false,"is_open_access":true,"raw_metadata":{"ooir":{"day":"2023-09-05","doi":"10.1016/j.jid.2023.01.039","days":"30","issn":"0022-202X","rank":"1","field":"Clinical Medicine","score":"679","category":"Dermatology","categories":["Dermatology"],"_categories":["Dermatology"]},"pubmed":{"doi":"10.1016/j.jid.2023.01.039","title":"Endolysin Inhibits Skin Colonization by Patient-Derived Staphylococcus Aureus and Malignant T-Cell Activation in Cutaneous T-Cell Lymphoma.","journal":"The Journal of investigative dermatology","methods":"","results":"","abstract":"$36","keywords":[],"pubmed_id":"36889662","conclusions":"","publication_date":"2023-03-09T00:00:00"},"crossref":{"DOI":"10.1016/j.jid.2023.01.039","URL":"https://doi.org/10.1016/j.jid.2023.01.039","ISSN":["0022-202X"],"link":[{"URL":"https://api.elsevier.com/content/article/PII:S0022202X23001756?httpAccept=text/xml","content-type":"text/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https://api.elsevier.com/content/article/PII:S0022202X23001756?httpAccept=text/plain","content-type":"text/plain","content-version":"vor","intended-application":"text-mining"}],"page":"1757-1768.e3","type":"journal-article","issue":"9","score":1,"title":["Endolysin Inhibits Skin Colonization by Patient-Derived Staphylococcus Aureus and Malignant T-Cell Activation in Cutaneous T-Cell Lymphoma"],"author":[{"given":"Emil M.H.","family":"Pallesen","sequence":"first","affiliation":[]},{"given":"Maria","family":"Gluud","sequence":"additional","affiliation":[]},{"given":"Chella Krishna","family":"Vadivel","sequence":"additional","affiliation":[]},{"given":"Terkild B.","family":"Buus","sequence":"additional","affiliation":[]},{"given":"Bob","family":"de Rooij","sequence":"additional","affiliation":[]},{"given":"Ziao","family":"Zeng","sequence":"additional","affiliation":[]},{"given":"Sana","family":"Ahmad","sequence":"additional","affiliation":[]},{"given":"Andreas","family":"Willerslev-Olsen","sequence":"additional","affiliation":[]},{"given":"Christian","family":"Röhrig","sequence":"additional","affiliation":[]},{"given":"Maria R.","family":"Kamstrup","sequence":"additional","affiliation":[]},{"given":"Lene","family":"Bay","sequence":"additional","affiliation":[]},{"given":"Lise","family":"Lindahl","sequence":"additional","affiliation":[]},{"given":"Thorbjørn","family":"Krejsgaard","sequence":"additional","affiliation":[]},{"given":"Carsten","family":"Geisler","sequence":"additional","affiliation":[]},{"given":"Charlotte M.","family":"Bonefeld","sequence":"additional","affiliation":[]},{"given":"Lars","family":"Iversen","sequence":"additional","affiliation":[]},{"given":"Anders","family":"Woetmann","sequence":"additional","affiliation":[]},{"given":"Sergei B.","family":"Koralov","sequence":"additional","affiliation":[]},{"given":"Thomas","family":"Bjarnsholt","sequence":"additional","affiliation":[]},{"given":"Johan","family":"Frieling","sequence":"additional","affiliation":[]},{"given":"Mathias","family":"Schmelcher","sequence":"additional","affiliation":[]},{"given":"Niels","family":"Ødum","sequence":"additional","affiliation":[]}],"issued":{"date-parts":[[2023,9]]},"member":"78","prefix":"10.1016","source":"Crossref","volume":"143","created":{"date-time":"2023-03-06T19:45:37Z","timestamp":1678131937000,"date-parts":[[2023,3,6]]},"indexed":{"date-time":"2025-09-20T21:53:10Z","timestamp":1758405190717,"date-parts":[[2025,9,20]]},"license":[{"URL":"https://www.elsevier.com/tdm/userlicense/1.0/","start":{"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000,"date-parts":[[2023,9,1]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"https://www.elsevier.com/legal/tdmrep-license","start":{"date-time":"2023-09-01T00:00:00Z","timestamp":1693526400000,"date-parts":[[2023,9,1]]},"delay-in-days":0,"content-version":"tdm"},{"URL":"http://creativecommons.org/licenses/by/4.0/","start":{"date-time":"2023-03-02T00:00:00Z","timestamp":1677715200000,"date-parts":[[2023,3,2]]},"delay-in-days":0,"content-version":"vor"}],"subject":[],"abstract":null,"language":"en","relation":{},"resource":{"primary":{"URL":"https://linkinghub.elsevier.com/retrieve/pii/S0022202X23001756"}},"subtitle":[],"assertion":[{"name":"publisher","label":"This article is maintained by","value":"Elsevier"},{"name":"articletitle","label":"Article Title","value":"Endolysin Inhibits Skin Colonization by Patient-Derived Staphylococcus Aureus and Malignant T-Cell Activation in Cutaneous T-Cell Lymphoma"},{"name":"journaltitle","label":"Journal Title","value":"Journal of Investigative Dermatology"},{"name":"articlelink","label":"CrossRef DOI link to publisher maintained version","value":"https://doi.org/10.1016/j.jid.2023.01.039"},{"name":"content_type","label":"Content Type","value":"article"},{"name":"copyright","label":"Copyright","value":"© 2023 The Authors. Published by Elsevier, Inc. on behalf of the Society for Investigative Dermatology."}],"deposited":{"date-time":"2025-09-19T17:33:56Z","timestamp":1758303236000,"date-parts":[[2025,9,19]]},"issn-type":[{"type":"print","value":"0022-202X"}],"published":{"date-parts":[[2023,9]]},"publisher":"Elsevier BV","reference":[{"DOI":"10.1080/08830185.2019.1677644","key":"10.1016/j.jid.2023.01.039_bib1","year":"2020","issue":null,"author":"Allam","volume":"39","first-page":"3","unstructured":null,"article-title":"The potential role of interleukin-37 in infectious diseases","journal-title":"Int Rev Immunol","doi-asserted-by":"crossref"},{"DOI":"10.1093/jncimonographs/lgu008","key":"10.1016/j.jid.2023.01.039_bib2","year":"2014","issue":null,"author":"Aschebrook-Kilfoy","volume":"2014","first-page":"98","unstructured":null,"article-title":"Medical history, lifestyle, family history, and occupational risk factors for mycosis fungoides and Sezary syndrome: the InterLymph Non-Hodgkin Lymphoma Subtypes Project","journal-title":"J Natl Cancer Inst Monogr","doi-asserted-by":"crossref"},{"DOI":"10.1001/jama.1992.03480100060031","key":"10.1016/j.jid.2023.01.039_bib3","year":"1992","issue":null,"author":"Axelrod","volume":"267","first-page":"1354","unstructured":null,"article-title":"Infections complicating mycosis fungoides and Sezary syndrome","journal-title":"JAMA","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1749-6632.2001.tb03708.x","key":"10.1016/j.jid.2023.01.039_bib4","year":"2001","issue":null,"author":"Bagot","volume":"941","first-page":"31","unstructured":null,"article-title":"Crosstalk between tumor T lymphocytes and reactive T lymphocytes in cutaneous T cell lymphomas","journal-title":"Ann N Y Acad Sci","doi-asserted-by":"crossref"},{"DOI":"10.1016/S1473-3099(21)00122-5","key":"10.1016/j.jid.2023.01.039_bib5","year":"2022","issue":null,"author":"Bjarnsholt","volume":"22","first-page":"e88","unstructured":null,"article-title":"The importance of understanding the infectious microenvironment","journal-title":"Lancet Infect Dis","doi-asserted-by":"crossref"},{"DOI":"10.1080/2162402X.2020.1751561","key":"10.1016/j.jid.2023.01.039_bib6","year":"2020","issue":null,"author":"Blümel","volume":"9","first-page":null,"unstructured":null,"article-title":"Staphylococcus aureus alpha-toxin inhibits CD8+ T cell-mediated killing of cancer cells in cutaneous T-cell lymphoma","journal-title":"Oncoimmunology","doi-asserted-by":"crossref"},{"DOI":"10.1080/2162402X.2019.1641387","key":"10.1016/j.jid.2023.01.039_bib7","year":"2019","issue":null,"author":"Blümel","volume":"8","first-page":null,"unstructured":null,"article-title":"Staphylococcal alpha-toxin tilts the balance between malignant and non-malignant CD4+ T cells in cutaneous T-cell lymphoma","journal-title":"Oncoimmunology","doi-asserted-by":"crossref"},{"DOI":"10.1182/blood.2021013341","key":"10.1016/j.jid.2023.01.039_bib8","year":"2022","issue":null,"author":"de Masson","volume":"139","first-page":"1820","unstructured":null,"article-title":"Macrophage-derived CXCL9 and CXCL11, T-cell skin homing, and disease control in mogamulizumab-treated CTCL patients","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0959-8049(21)00631-6","key":"10.1016/j.jid.2023.01.039_bib9","year":"2021","issue":null,"author":"Dobos","volume":"156","first-page":"S3","unstructured":null,"article-title":"Exploring the role of the skin microenvironment in cutaneous T-cell lymphoma using single cell RNA-sequencing","journal-title":"Eur J Cancer","doi-asserted-by":"crossref"},{"DOI":"10.1111/bjd.19644","key":"10.1016/j.jid.2023.01.039_bib10","year":"2021","issue":null,"author":"Dobos","volume":"184","first-page":"1059","unstructured":null,"article-title":"Epidemiological changes in cutaneous lymphomas: an analysis of 8593 patients from the French cutaneous Lymphoma Registry","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1038/s41572-021-00296-9","key":"10.1016/j.jid.2023.01.039_bib11","year":"2021","issue":null,"author":"Dummer","volume":"7","first-page":"61","unstructured":null,"article-title":"Cutaneous T cell lymphoma","journal-title":"Nat Rev Dis Primers","doi-asserted-by":"crossref"},{"DOI":"10.1016/S0190-9622(80)80385-9","key":"10.1016/j.jid.2023.01.039_bib12","year":"1980","issue":null,"author":"Edelson","volume":"2","first-page":"89","unstructured":null,"article-title":"Cutaneous T cell lymphoma: mycosis fungoides, Sezary syndrome, and other variants","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1749-6632.2001.tb03705.x","key":"10.1016/j.jid.2023.01.039_bib13","year":"2001","issue":null,"author":"Edelson","volume":"941","first-page":"1","unstructured":null,"article-title":"Cutaneous T cell lymphoma: the helping hand of dendritic cells","journal-title":"Ann N Y Acad Sci","doi-asserted-by":"crossref"},{"DOI":"10.1128/aac.02273-21","key":"10.1016/j.jid.2023.01.039_bib14","year":"2022","issue":null,"author":"Eichenseher","volume":"66","first-page":null,"unstructured":null,"article-title":"Linker-improved chimeric endolysin selectively kills Staphylococcus aureus in vitro, on reconstituted human epidermis, and in a murine model of skin infection","journal-title":"Antimicrob Agents Chemother","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00403-019-02015-7","key":"10.1016/j.jid.2023.01.039_bib15","year":"2020","issue":null,"author":"Emge","volume":"312","first-page":"283","unstructured":null,"article-title":"Methicillin-resistant Staphylococcus aureus (MRSA) is an important pathogen in erythrodermic cutaneous T-cell lymphoma (CTCL) patients","journal-title":"Arch Dermatol Res","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jid.2017.10.028","key":"10.1016/j.jid.2023.01.039_bib16","year":"2018","issue":null,"author":"Fanok","volume":"138","first-page":"1116","unstructured":null,"article-title":"Role of dysregulated cytokine signaling and bacterial triggers in the pathogenesis of cutaneous T-cell lymphoma","journal-title":"J Invest Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/exd.12455","key":"10.1016/j.jid.2023.01.039_bib17","year":"2014","issue":null,"author":"Geskin","volume":"23","first-page":"598","unstructured":null,"article-title":"Distinct age-matched serum biomarker profiles in patients with cutaneous T-cell lymphoma","journal-title":"Exp Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1182/blood.2022016690","key":"10.1016/j.jid.2023.01.039_bib18","year":"2023","issue":null,"author":"Gluud","volume":"141","first-page":"180","unstructured":null,"article-title":"Malignant T cells induce skin barrier defects through cytokine-mediated JAK/STAT signalling in cutaneous T-cell lymphoma","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":"10.3390/cancers12051229","key":"10.1016/j.jid.2023.01.039_bib19","year":"2020","issue":null,"author":"Gluud","volume":"12","first-page":"1229","unstructured":null,"article-title":"MicroRNAs in the pathogenesis, diagnosis, prognosis and targeted treatment of cutaneous T-cell lymphomas","journal-title":"Cancers (Basel)","doi-asserted-by":"crossref"},{"DOI":"10.1146/annurev.iy.09.040191.003525","key":"10.1016/j.jid.2023.01.039_bib20","year":"1991","issue":null,"author":"Herman","volume":"9","first-page":"745","unstructured":null,"article-title":"Superantigens: mechanism of T-cell stimulation and role in immune responses","journal-title":"Annu Rev Immunol","doi-asserted-by":"crossref"},{"DOI":"10.1182/blood.2020009346","key":"10.1016/j.jid.2023.01.039_bib21","year":"2021","issue":null,"author":"Herrera","volume":"138","first-page":"1456","unstructured":null,"article-title":"Multimodal single-cell analysis of cutaneous T-cell lymphoma reveals distinct subclonal tissue-dependent signatures","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.clindermatol.2019.01.004","key":"10.1016/j.jid.2023.01.039_bib22","year":"2019","issue":null,"author":"Hodak","volume":"37","first-page":"255","unstructured":null,"article-title":"Mycosis fungoides: A great imitator","journal-title":"Clin Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1182/blood.V89.1.32.32_32_40","key":"10.1016/j.jid.2023.01.039_bib23","year":"1997","issue":null,"author":"Jackow","volume":"89","first-page":"32","unstructured":null,"article-title":"Association of Erythrodermic cutaneous T-cell lymphoma, superantigen-positive Staphylococcus aureus, and oligoclonal T-cell receptor V beta gene expansion","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":"10.1371/journal.pone.0228751","key":"10.1016/j.jid.2023.01.039_bib24","year":"2020","issue":null,"author":"Kadin","volume":"15","first-page":null,"unstructured":null,"article-title":"Evidence linking atopy and staphylococcal superantigens to the pathogenesis of lymphomatoid papulosis, a recurrent CD30+ cutaneous lymphoproliferative disorder","journal-title":"PLoS One","doi-asserted-by":"crossref"},{"DOI":"10.1007/BF00431220","key":"10.1016/j.jid.2023.01.039_bib25","year":"1987","issue":null,"author":"Kaltoft","volume":"279","first-page":"293","unstructured":null,"article-title":"A continuous T-cell line from a patient with Sezary syndrome","journal-title":"Arch Dermatol Res","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1365-2133.1984.tb04727.x","key":"10.1016/j.jid.2023.01.039_bib26","year":"1984","issue":null,"author":"Kaltoft","volume":"111","first-page":"303","unstructured":null,"article-title":"Establishment of T and B cell lines from patients with mycosis fungoides","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/S1470-2045(18)30379-6","key":"10.1016/j.jid.2023.01.039_bib27","year":"2018","issue":null,"author":"Kim","volume":"19","first-page":"1192","unstructured":null,"article-title":"Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial","journal-title":"Lancet Oncol","doi-asserted-by":"crossref"},{"DOI":"10.1007/s00281-016-0594-9","key":"10.1016/j.jid.2023.01.039_bib28","year":"2017","issue":null,"author":"Krejsgaard","volume":"39","first-page":"269","unstructured":null,"article-title":"Malignant inflammation in cutaneous T-cell lymphoma-a hostile takeover","journal-title":"Semin Immunopathol","doi-asserted-by":"crossref"},{"DOI":"10.1182/blood-2013-01-480889","key":"10.1016/j.jid.2023.01.039_bib29","year":"2013","issue":null,"author":"Krejsgaard","volume":"122","first-page":"943","unstructured":null,"article-title":"Elucidating the role of interleukin-17F in cutaneous T-cell lymphoma","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":"10.1038/sj.leu.2404350","key":"10.1016/j.jid.2023.01.039_bib30","year":"2006","issue":null,"author":"Krejsgaard","volume":"20","first-page":"1759","unstructured":null,"article-title":"Jak3- and JNK-dependent vascular endothelial growth factor expression in cutaneous T-cell lymphoma","journal-title":"Leukemia","doi-asserted-by":"crossref"},{"DOI":"10.1080/08927014.2021.1887151","key":"10.1016/j.jid.2023.01.039_bib31","year":"2021","issue":null,"author":"Kuiper","volume":"37","first-page":"184","unstructured":null,"article-title":"The novel endolysin XZ.700 effectively treats MRSA biofilms in two biofilm models without showing toxicity on human bone cells in vitro","journal-title":"Biofouling","doi-asserted-by":"crossref"},{"DOI":"10.1111/ijd.13832","key":"10.1016/j.jid.2023.01.039_bib32","year":"2018","issue":null,"author":"Lewis","volume":"57","first-page":"123","unstructured":null,"article-title":"The \"Duvic regimen\" for erythrodermic flares secondary to Staphylococcus aureus in mycosis fungoides and Sezary syndrome","journal-title":"Int J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1159/000517829","key":"10.1016/j.jid.2023.01.039_bib33","year":"2022","issue":null,"author":"Lindahl","volume":"238","first-page":"551","unstructured":null,"article-title":"Staphylococcus aureus and antibiotics in cutaneous T-cell Lymphoma","journal-title":"Dermatology","doi-asserted-by":"crossref"},{"DOI":"10.1182/blood.2018888107","key":"10.1016/j.jid.2023.01.039_bib34","year":"2019","issue":null,"author":"Lindahl","volume":"134","first-page":"1072","unstructured":null,"article-title":"Antibiotics inhibit tumor and disease activity in cutaneous T-cell lymphoma","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":"10.1186/s12885-021-08142-7","key":"10.1016/j.jid.2023.01.039_bib35","year":"2021","issue":null,"author":"Mehdi","volume":"21","first-page":"492","unstructured":null,"article-title":"Normal and cancer fibroblasts differentially regulate TWIST1, TOX and cytokine gene expression in cutaneous T-cell lymphoma","journal-title":"BMC Cancer","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jaad.2009.11.692","key":"10.1016/j.jid.2023.01.039_bib36","year":"2011","issue":null,"author":"Mirvish","volume":"64","first-page":"423","unstructured":null,"article-title":"Infectious agents in cutaneous T-cell lymphoma","journal-title":"J Am Acad Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.ccell.2017.05.008","key":"10.1016/j.jid.2023.01.039_bib37","year":"2017","issue":null,"author":"Qu","volume":"32","first-page":"27","unstructured":null,"article-title":"Chromatin accessibility landscape of cutaneous T cell lymphoma and dynamic response to HDAC inhibitors","journal-title":"Cancer Cell","doi-asserted-by":"crossref"},{"DOI":"10.3109/10428199609045718","key":"10.1016/j.jid.2023.01.039_bib38","year":"1996","issue":null,"author":"Sarris","volume":"24","first-page":"103","unstructured":null,"article-title":"Interferon-inducible protein-10 and the pathogenesis of cutaneous T-cell lymphomas","journal-title":"Leuk Lymphoma","doi-asserted-by":"crossref"},{"DOI":"10.1182/blood.V86.2.651.bloodjournal862651","key":"10.1016/j.jid.2023.01.039_bib39","year":"1995","issue":null,"author":"Sarris","volume":"86","first-page":"651","unstructured":null,"article-title":"Cytokine loops involving interferon-gamma and IP-10, a cytokine chemotactic for CD4+ lymphocytes: an explanation for the epidermotropism of cutaneous T-cell lymphoma?","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":"10.2217/fmb.12.97","key":"10.1016/j.jid.2023.01.039_bib40","year":"2012","issue":null,"author":"Schmelcher","volume":"7","first-page":"1147","unstructured":null,"article-title":"Bacteriophage endolysins as novel antimicrobials","journal-title":"Future Microbiol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.copbio.2020.09.012","key":"10.1016/j.jid.2023.01.039_bib41","year":"2021","issue":null,"author":"Schmelcher","volume":"68","first-page":"51","unstructured":null,"article-title":"Bacteriophage endolysins - extending their application to tissues and the bloodstream","journal-title":"Curr Opin Biotechnol","doi-asserted-by":"crossref"},{"DOI":"10.1093/jac/dku552","key":"10.1016/j.jid.2023.01.039_bib42","year":"2015","issue":null,"author":"Schmelcher","volume":"70","first-page":"1453","unstructured":null,"article-title":"Evolutionarily distinct bacteriophage endolysins featuring conserved peptidoglycan cleavage sites protect mice from MRSA infection","journal-title":"J Antimicrob Chemother","doi-asserted-by":"crossref"},{"DOI":"10.3389/fcell.2020.00851","key":"10.1016/j.jid.2023.01.039_bib43","year":"2020","issue":null,"author":"Stolearenco","volume":"8","first-page":"851","unstructured":null,"article-title":"Cellular interactions and inflammation in the pathogenesis of cutaneous T-cell lymphoma","journal-title":"Front Cell Dev Biol","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1365-2133.2008.08612.x","key":"10.1016/j.jid.2023.01.039_bib44","year":"2008","issue":null,"author":"Talpur","volume":"159","first-page":"105","unstructured":null,"article-title":"Prevalence and treatment of Staphylococcus aureus colonization in patients with mycosis fungoides and Sezary syndrome","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1182/blood.2019004256","key":"10.1016/j.jid.2023.01.039_bib45","year":"2022","issue":null,"author":"Tensen","volume":"139","first-page":"15","unstructured":null,"article-title":"Genetic and epigenetic insights into cutaneous T-cell lymphoma","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":"10.1046/j.1523-1747.1998.00263.x","key":"10.1016/j.jid.2023.01.039_bib46","year":"1998","issue":null,"author":"Tensen","volume":"111","first-page":"222","unstructured":null,"article-title":"Epidermal interferon-gamma inducible protein-10 (IP-10) and monokine induced by gamma-interferon (Mig) but not IL-8 mRNA expression is associated with epidermotropism in cutaneous T cell lymphomas","journal-title":"J Invest Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/1523-1747.ep12494184","key":"10.1016/j.jid.2023.01.039_bib47","year":"1992","issue":null,"author":"Tokura","volume":"98","first-page":"33","unstructured":null,"article-title":"Stimulation of cutaneous T-cell lymphoma cells with superantigenic staphylococcal toxins","journal-title":"J Invest Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1111/j.1365-2133.1995.tb02485.x","key":"10.1016/j.jid.2023.01.039_bib48","year":"1995","issue":null,"author":"Tokura","volume":"133","first-page":"6","unstructured":null,"article-title":"Cutaneous colonization with staphylococci influences the disease activity of Sezary syndrome: a potential role for bacterial superantigens","journal-title":"Br J Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jid.2016.03.042","key":"10.1016/j.jid.2023.01.039_bib49","year":"2016","issue":null,"author":"van Doorn","volume":"136","first-page":"1876","unstructured":null,"article-title":"Epigenomic analysis of Sezary syndrome defines patterns of aberrant DNA methylation and identifies diagnostic markers","journal-title":"J Invest Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1172/jci.insight.124233","key":"10.1016/j.jid.2023.01.039_bib50","year":"2019","issue":null,"author":"Vieyra-Garcia","volume":"4","first-page":null,"unstructured":null,"article-title":"Benign T cells drive clinical skin inflammation in cutaneous T cell lymphoma","journal-title":"JCI Insight","doi-asserted-by":"crossref"},{"DOI":"10.1038/s41408-020-0324-3","key":"10.1016/j.jid.2023.01.039_bib51","year":"2020","issue":null,"author":"Willerslev-Olsen","volume":"10","first-page":"57","unstructured":null,"article-title":"Staphylococcus aureus enterotoxins induce FOXP3 in neoplastic T cells in Sezary syndrome","journal-title":"Blood Cancer J","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jid.2021.01.038","key":"10.1016/j.jid.2023.01.039_bib52","year":"2021","issue":null,"author":"Willerslev-Olsen","volume":"141","first-page":"2449","unstructured":null,"article-title":"Staphylococcus aureus induces signal transducer and activator of transcription 5-dependent miR-155 expression in cutaneous T-cell lymphoma","journal-title":"J Invest Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.3390/toxins5081402","key":"10.1016/j.jid.2023.01.039_bib53","year":"2013","issue":null,"author":"Willerslev-Olsen","volume":"5","first-page":"1402","unstructured":null,"article-title":"Bacterial toxins fuel disease progression in cutaneous T-cell lymphoma","journal-title":"Toxins (Basel)","doi-asserted-by":"crossref"},{"DOI":"10.1182/blood-2015-08-662353","key":"10.1016/j.jid.2023.01.039_bib54","year":"2016","issue":null,"author":"Willerslev-Olsen","volume":"127","first-page":"1287","unstructured":null,"article-title":"Staphylococcal enterotoxin A (SEA) stimulates STAT3 activation and IL-17 expression in cutaneous T-cell lymphoma","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":"10.1182/blood-2006-04-017863","key":"10.1016/j.jid.2023.01.039_bib55","year":"2007","issue":null,"author":"Woetmann","volume":"109","first-page":"3325","unstructured":null,"article-title":"Nonmalignant T cells stimulate growth of T-cell lymphoma cells in the presence of bacterial toxins","journal-title":"Blood","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jid.2019.11.018","key":"10.1016/j.jid.2023.01.039_bib56","year":"2020","issue":null,"author":"Wu","volume":"140","first-page":"1390","unstructured":null,"article-title":"A small molecule CCR2 antagonist depletes tumor macrophages and synergizes with anti-PD-1 in a murine model of cutaneous T-cell lymphoma (CTCL)","journal-title":"J Invest Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1038/jid.2009.45","key":"10.1016/j.jid.2023.01.039_bib57","year":"2009","issue":null,"author":"Wu","volume":"129","first-page":"1115","unstructured":null,"article-title":"Cutaneous T-cell lymphoma: roles for chemokines and chemokine receptors","journal-title":"J Invest Dermatol","doi-asserted-by":"crossref"},{"DOI":"10.1016/j.jid.2022.01.009","key":"10.1016/j.jid.2023.01.039_bib58","year":"2022","issue":null,"author":"Yu","volume":"142","first-page":"2285","unstructured":null,"article-title":"IL-32 supports the survival of malignant T cells in cutaneous T-cell lymphoma","journal-title":"J Invest Dermatol","doi-asserted-by":"crossref"}],"short-title":[],"journal-issue":{"issue":"9","published-print":{"date-parts":[[2023,9]]}},"update-policy":"https://doi.org/10.1016/elsevier_cm_policy","alternative-id":["S0022202X23001756"],"content-domain":{"domain":["jidonline.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"original-title":[],"container-title":["Journal of Investigative Dermatology"],"published-print":{"date-parts":[[2023,9]]},"reference-count":58,"published-online":null,"references-count":58,"short-container-title":["Journal of Investigative Dermatology"],"is-referenced-by-count":24},"unpaywall":{"doi":"10.1016/j.jid.2023.01.039","is_oa":true,"title":"Endolysin Inhibits Skin Colonization by Patient-Derived Staphylococcus Aureus and Malignant T-Cell Activation in Cutaneous T-Cell Lymphoma","updated":"2025-09-06T02:51:56+00:00","published_date":"2023-03-07","best_oa_location":{"url":"http://www.jidonline.org/article/S0022202X23001756/pdf","pmh_id":null,"url_for_pdf":"http://www.jidonline.org/article/S0022202X23001756/pdf","url_for_landing_page":"https://doi.org/10.1016/j.jid.2023.01.039"}}},"created_at":"2025-09-21T02:45:33.092Z","updated_at":"2025-09-21T04:29:22.836Z","tags":[{"paper_doi":"10.1016/j.jid.2023.01.039","tag_type":"age_group","value":"adult","value_numeric":null},{"paper_doi":"10.1016/j.jid.2023.01.039","tag_type":"brand","value":"XZ.700","value_numeric":null},{"paper_doi":"10.1016/j.jid.2023.01.039","tag_type":"category","value":"Dermatology","value_numeric":null},{"paper_doi":"10.1016/j.jid.2023.01.039","tag_type":"condition","value":"Cutaneous T-Cell Lymphoma","value_numeric":null},{"paper_doi":"10.1016/j.jid.2023.01.039","tag_type":"impact_flag","value":"limited_evidence","value_numeric":null},{"paper_doi":"10.1016/j.jid.2023.01.039","tag_type":"modality","value":"Endolysin","value_numeric":null},{"paper_doi":"10.1016/j.jid.2023.01.039","tag_type":"study_design","value":"Preclinical Study","value_numeric":null},{"paper_doi":"10.1016/j.jid.2023.01.039","tag_type":"warning","value":"Design classification is approximate; this is an in vitro and ex vivo preclinical study, not a clinical trial.","value_numeric":null},{"paper_doi":"10.1016/j.jid.2023.01.039","tag_type":"warning","value":"Human lesional skin testing was limited (five sites from three patients), and bacterial isolate diversity was small.","value_numeric":null},{"paper_doi":"10.1016/j.jid.2023.01.039","tag_type":"warning","value":"Several authors report relationships with the company developing XZ.700, which may introduce bias.","value_numeric":null}],"summaries":{"what_studied":"Preclinical in vitro and ex vivo experiments tested a recombinant anti–Staphylococcus aureus endolysin (XZ.700) on patient-derived S. aureus growth, skin colonization (healthy and lesional CTCL skin), and S. aureus–driven malignant T‑cell activation/proliferation.","key_result":"XZ.700 cut S. aureus counts by ≥4-log CFU at ≥1 mg/mL within 1 hour and dropped SEA toxin from >15 ng/mL to <1 ng/mL at 4 hours; on skin, 1 µg/mL coaddition nearly prevented colonization and 10 µg/mL after colonization almost eradicated bacteria, while also suppressing S. aureus–induced IFNγ/CXCL10 and blocking CD25/pSTAT5 and Ki‑67 increases in malignant T cells in coculture.","limitations":"Findings are limited to laboratory and ex vivo models with small human tissue samples (five lesional sites from three patients), using few bacterial isolates; several authors are affiliated with the endolysin’s developer.","practice_takeaway":"In CTCL models, targeted S. aureus killing with an endolysin curtailed skin colonization and halted S. aureus–driven malignant T‑cell activation, suggesting a potential nonantibiotic decolonization strategy that warrants clinical testing."}}],"initialOffset":11,"fetchConfig":{"kind":"tags","tags":[{"tag_type":"condition","value":"Cutaneous T-Cell Lymphoma"}]},"breadcrumbItems":[{"name":"Home","href":"/"},{"name":"Research Hub","href":"/hub"},{"name":"Conditions","href":"/hub/tag/condition"},{"name":"Cutaneous T-Cell Lymphoma"}],"hrefConfig":{"basePath":"/hub/papers","webViewQueryParams":{"hub_ctx":"tag","hub_tag_type":"condition","hub_tag_value":"Cutaneous T-Cell Lymphoma"}}}]]

Papers